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Cancer is characterized by an abnormal expansion of cells, which leads to invasion and destruction of 
surrounding tissues. A single precursor will divide without respect of normal limits, and this behavior 
differentiates a malignant tumor from a benign one, which is self-limited in its growth, and does not 
invade or metastasize (although some benign tumors may be precursors to malignant ones). 
The most significant difference between benign and malignant tumors is the metastatic potential 
of the latter. Individual tumor cells may dislodge from the primary tumor and spread via the blood 
(hematogenous spread) or lymphatic vessels (lymphatic spread) and form secondary tumors at distant 
anatomic locations. Cancer may affect people at all ages, but the risk of developing one of the more 
common varieties tends to increase with age. Together they are the second leading cause of death 
in the Netherlands, affecting over 95.000 people annually. In 2009, over 42.500 people died from 
cancer, which has serious psychological, social and financial consequences (Integraal Kankercentrum 
Nederland, 2010).
Cancer is caused by abnormalities in the genetic material of the tumor cells (Knudson, 2002; Duesberg 
et al., 2005). This genetic damage may be inherited in the germline, acquired by the action of chemicals, 
radiation, or micro-organisms, or a combination of these. New aspects of the genetics of cancer 
pathogenesis, such as epigenetic alterations in the genes responsible for sensing, interpreting, and 
responding to tissue-specific homeostatic signals are increasingly being recognized as important 
(Laird and Jaenisch, 1996; Gopalakrishnan et al., 2008; Howell Jr. et al., 2009). The phenotype of the 
cancerous cell may arise either from genetic alterations that disrupt gene function through sequence 
modifications (mutations or deletions) or epigenetic modifications that may alter the gene expression 
(without changing the nucleotide sequence of the genome).
Genes involved in cancer
Several processes are involved in cancer, but because a fundamental characteristic of cancer cells is 
their uncontrolled proliferation, it is not surprising that many cancer-related genes are involved in the 
normal cell-cycle regulation (Hanahan and Weinberg 2000; Hanahan and Weinberg, 2011). Some of 
these genes control cell growth, or stop excessive cell growth, while others control a cell’s blood supply 
or its metastatic spread. Genetic abnormalities found in cancer typically affect two classes of genes. The 
classes are often referred to as oncogenes and tumor-suppressor genes, depending on whether cancer-
causing mutations result in gain or loss of function, respectively. Cancer-promoting oncogenes are 
often activated in cancer cells, giving those cells new properties, such as continued growth and division, 
protection against programmed cell death, disruption of tissue boundaries, and the ability to become 
established in diverse tissue environments. Oncogenes can encode signaling molecules such as growth 
factors, or components of the signaling cascades that regulate cellular responses. Tumor-suppressor 
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genes are often inactivated in cancer cells, resulting in the loss of normal function in those cells, such as 
accurate DNA replication, control over the cell cycle, orientation and adhesion within tissues, and their 
interaction with protective cells of the immune system. Mutations can knock out a cell-surface receptor 
for inhibiting factors, or a critical component of the cascades inside the cell that receive and process the 
signal. Other mutations can disable proteins such as p53, which trigger the cell to undergo apoptosis 
(commit suicide) if the cell’s DNA becomes damaged, or when the cell’s signaling cascades go out of 
control. It is commonly assumed that cancer results from a stepwise accumulation of acquired and 
uncorrected somatic mutations, which is probably also the case in uveal melanoma.
Introduction to uveal melanoma
Melanocytes in the human eye
Melanocytes are melanin-producing cells that provide important physiological functions in the skin, eye, 
inner ear and meninges (Tolleson, 2005). Recognized functions associated with melanin production in 
humans include photo-protection, trapping of reactive oxygen species, sequestering metal ions, and 
binding certain drugs and organic chemicals (Riley, 1992; Riley, 1997). The largest numbers of melanocytes 
are found in the skin and hair follicles. Another large population resides within the uveal tract of the eye, 
which embryologically consists of the choroid, ciliary body and iris. Melanocytes from the uveal tract are 
derived from neural crest cells of the neurectoderm, which migrate following neural tube closure. Neural 
crest cells migrate to the uveal tract, where they develop into melanocytes. Ocular melanocyte cell 
numbers vary with age, race and general pigmentation: they are most numerous around the optic disc, 
less so in the periphery and the inner choroid. Melanocytes determine the pigmentation of the choroid 
in the mature eye and occur in the choroidal stroma, providing its brown color. The major determinant 
of color is not the number but rather the activity of the melanocytes. Melanin production takes place 
in unique organelles known as melanosomes. Darkly pigmented choroids have melanosomes that 
contain more eumelanin, the most common form of melanin. Choroidal melanocytes form an almost 
continuous layer in the outer choroid, spreading in the plane of the choroidal space and forming a thin 
three-dimensional network. This provides melanocytes within the highly vascularized uveal tract with a 
markedly different microenvironment compared to cutaneous melanocytes that are distributed among 
clusters of keratinocytes.
Uveal melanoma
A normal uveal melanocyte that acquires malignant properties can develop into a uveal melanoma. 
Although uveal melanocytes are of the same embryological origin as cutaneous melanocytes, uveal 
melanomas seem to have a totally different incidence, prevalence and metastatic behavior as skin 
melanoma. It should be noted that wherever the term uveal melanoma is used in this thesis, it refers 
to melanoma of the choroid and/or ciliary body. Melanomas of the iris, the third part of the uvea, are 





body by their smaller size and relatively benign pathogenesis (Ashton and Wybar, 1966; Jakobiec and 
Silbert, 1981). Also, their clinical appearance and treatment are totally different (Rones and Zimmermann, 
1958).
Epidemiology
Approximately 5% of all malignant melanomas arise in ocular and adnexal structures (Singh and 
Topham, 2003a). Most ocular melanomas are uveal in origin, whereas primary conjunctival and orbital 
melanomas are very rare (Chang et al., 1998; Singh and Topham, 2003a). Uveal melanoma accounts for 
70% of all primary eye tumors and occurs at an annual incidence of 6 to 8 cases per million people in 
Caucasian populations (Egan et al., 1988). The age-adjusted annual incidence rate for uveal melanoma in 
the United States (4.3 per million) has remained stable for the past 25 years and is similar to that reported 
in European countries (Singh and Topham, 2003a). 
Recently, a European analysis of incidence of uveal melanoma in Europe between 1983 and 1994, as 
well as its geographic and temporal variation, using cancer registry data collected in the framework 
of the EUROCARE project, also reported a stable incidence of uveal melanoma (Virgili et al., 2008). 
Interestingly, a north-to south decreasing gradient was found, with standardized incidence rates from 
a minimum of less than 2 per million in Spain and southern Italy to more than 8 per million in Norway 
and Denmark. Other studies in France and Denmark have found an incidence of about 7 per million 
(Vidal et al., 1995; Isager et al., 2005). This incidence is 15 to 50 times lower in Africans and Orientals 
(Egan et al., 1988). Highest incidence rates are observed in Northern Europe and Australia and the lowest 
rates among Asian, Hispanic, and black populations, consistent with other observations of lower rates 
of uveal melanoma in pigmented people (Margo et al., 1998; Vajdic et al., 2003; Hu et al., 2008). The 
incidence increases between ages 30 and 70 and most often this tumor is observed in the sixth decade 
of life (Jensen, 1963; Singh and Topham, 2003a). Although uveal melanoma has been recognized and 
treated for over a century, its cause is only recently being uncovered (Van Raamsdonk et al, 2008; Van 
Raamsdonk et al., 2010).
Diagnosis and Treatment
About 60% of patients present with complaints such as blurred or distorted vision, visual field loss, floaters 
or photopsia (Damato, 2001). Sometimes uveal melanomas cause no symptoms and are discovered 
on routine ocular examination by ophthalmoscopy. About 10% of cases are asymptomatic, usually 
corresponding to small or medium-sized tumors situated close to the equator of the eye, discovered 
incidentally on routine ocular fundus examination, such as after cataract surgery. On visual examination, 
uveal melanomas typically appear as discrete solid tumors, sometimes causing a secondary serous 
retinal detachment, which can be responsible for visual loss. They may frequently break through Bruch’s 
membrane, extending into the subsensory retinal space. Uveal melanomas may display a discoid, dome-
shaped or mushroom-shaped growth pattern. The retina overlying the tumor may show degenerative 
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changes, occasionally to the point of complete attenuation with tumor perforation into the vitreous 
cavity. On top of the choroidal melanoma, orange pigment, lipofuscin, may be present. Pigment is due to 
naturally occurring melanin that comes from melanocytes in the choroidal layer. Choroidal melanomas 
are usually pigmented, but they can be variably pigmented and even amelanotic (non-pigmented). 
Non-pigmented choroidal melanoma is due to a proliferation of melanocytes that have lost their ability 
to make melanin pigment. While this configuration is not diagnostic and limited to uveal melanoma, 
it is highly characteristic. The Collaborative Ocular Melanoma Study (COMS) showed that the accuracy 
of correct clinical diagnosis in uveal melanoma is extremely high and can be made based on fundus 
examination and echography (COMS report no.1., 1990).
Increased understanding and awareness of the disease appears to have led to enhanced diagnosis of 
patients with smaller size lesions (COMS report no.20., 2003). However, patient survival has remained 
poor, presumably due to silent hematogenous spreading of micro-metastases prior to the diagnosis of 
clinically evident disease (Eskelin et al., 2000; Singh and Topham, 2003b; Virgili et al., 2008). At present, it 
is considered acceptable to delay treatment of melanocytic tumors of indeterminate malignancy until 
growth is documented (Shields et al., 1995; COMS report no.5., 1997).  Fine-needle aspiration biopsy 
(FNAB) is used in some centers to establish a diagnosis (Sisley et al., 1998; Augsburger et al., 2002). 
However, the use of FNAB’s for prognosis is still under debate (Sandinha et al., 2006; Maat et al., 2007; 
Schoenfield et al., 2009). 
Once the diagnosis of primary uveal melanoma has been made, several treatment modalities are 
available. In the past, enucleation of the tumor-bearing eye was the only treatment option for uveal 
melanoma. During the last decades, more eye-conserving treatment modalities have become available. 
Nowadays, the primary uveal melanoma can often be managed successfully with preservation of the 
eye and its remaining visual function. Plaque-brachytherapy, particle beam radiotherapy, stereotactic 
radiotherapy, thermotherapy, transscleral local resection, transretinal resection and diode laser 
phototherapy are treatment modalities used around the world (Rousseau, 2004; Damato, 2006). In 
Leiden, plaque-brachytherapy with ruthenium-106 is the current mode of treatment for small to 
medium-sized tumors. Large or recurrent tumors may undergo proton-beam therapy or enucleation 
(Keunen and Bleeker, 1997; Keunen et al., 1999).
It should be noted that despite the introduction of these new treatment modalities and diagnostic 
advances, the rate of metastatic disease has not substantially declined. Untreated, uveal melanomas 
tend to cause severe loss of vision and eventually an inflamed, unsightly and painful eye. However, a 
large tumor size in choroidal melanoma decreases the chance that vision-sparing treatments will be 
successful. In general, the larger the choroidal melanoma, the worse the prognosis for both vision and 
metastasis (Shields et al., 2009). For uveal melanoma metastases, no effective treatment has been found 





results in selected cases (Pyrhonen, 1998; Missotten and Keunen, 2004). Other treatment modalities 
are general chemotherapy, chemo-immunotherapy, intra-arterial liver chemotherapy, isolated liver 
perfusion and immunotherapy (Ksander and Chen, 1999; Becker et al., 2002; Noter et al., 2004; Peters et 
al., 2006; Schmittel et al., 2006).
Metastases and survival
Approximately 40% to 50% of patients with uveal melanoma will ultimately develop metastases. At 
the time of diagnosis, over 99% have disease limited to the eye, but at least 30% of these patients will 
die of systemic metastases at 5 years and 45% at 15 years follow up (Kujala et al., 2003). Metastasis is 
by vascular spread, as the eye lacks lymphatic vessels and, consequently, the liver is involved first in up 
to 95% of patients who develop metastatic disease (Char, 1978; Lorigan et al., 1991; Gragoudas et al., 
1991). Metastases to the liver remain the primary cause of most morbidity and nearly all mortality in 
patients with advanced uveal melanoma. When dissemination is diagnosed, 60% of patients have liver 
metastases and post-mortem examination revealed a more than 90% incidence of metastatic disease 
(Lorigan et al., 1991). The presence of hepatic metastases is associated with a poor survival with an 
average median survival of only 6 to 8 months (Bedikian et al., 1981; Bedikian et al., 1995; Kujala et al., 
2003).
Predisposing factors
Several parameters that predispose to uveal melanoma have been described, including phenotypic 
risk factors. There is an elevated risk for Northern European and British ancestry as compared with 
Southern European or other Mediterranean heritage (Seddon et al., 1990). The racial predisposition has 
been explained on the basis of susceptibility of Caucasians to the oncogenic effect of sunlight. Several 
lines of investigation provide support both in favor and against a role for sunlight in the development 
of uveal melanoma (Egan et al., 1988; Dolin et al., 1994; Moan et al., 2008; Schmidt-Pokrzywniak et al., 
2009). Although there is epidemiological data that support the hypothesis that ultraviolet radiation 
contributes to cutaneous melanoma, no conclusive judgment about the role of sunlight exposure in 
uveal melanoma can be made (Singh et al., 2004). Host susceptibility factors such as iris color, skin color, 
hair color and ability to tan are also reported to be associated with uveal melanoma. Blue or grey iris 
colors appear to be associated with an increased risk for uveal melanoma, as do fair skin color, red or 
blond hair color, the inability to tan and for the presence of more atypical naevi (Seddon et al., 1990; van 
Hees et al., 1994; Hammer et al., 1996; Regan et al., 1999; Stang et al., 2003; Richtig et al., 2004; Weis et al., 
2006; Smith et al., 2007). 
Clinical, histopathological and immunological parameters
Many clinical factors have a proven prognostic value in uveal melanoma and a wide variety of parameters 
have been related to survival. However, few are specific. Major well-known and established factors are 
age, large basal tumor diameter, tumor prominence or thickness, tumor involvement of the ciliary body, 
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extrascleral extension, growth rate, and initial tumor regression rate after radiotherapy (Augsburger and 
Gamel, 1990; Mooy et al., 1991; Bedikian et al., 2008). Histopathological prognostic factors include location 
(iris, ciliary body or choroid), extraocular extension, growth pattern, cell type (Callender classification; 
Callender, 1931) or its modification (McLean et al., 1978; McLean et al., 1983), the number of mitosis, and 
the presence of tumor-infiltrating lymphocytes and macrophages and specific vasculogenic mimicry 
patterns (Seddon et al., 1983a; Coleman et al., 1993; Folberg et al., 1993; Foss et al., 1996; Foss et al., 1997).
Other important parameters related to prognosis include immunological determinants such as Human 
Leukocyte Antigen (HLA) expression and leukocyte infiltration (de la Cruz Jr. et al., 1990; de Waard-Siebinga 
et al., 1996; Blom et al., 1997; Ericsson et al., 2001; Dithmar et al., 2002; Jager et al., 2002). Correlations 
between certain HLA alleles and specific diseases have been described in autoimmune disorders 
(Lopez-Larrea et al., 1998). Also, correlations between HLA antigens and cutaneous melanoma have 
been reported: HLA-B40, -DR4, and –DR5 were found to be related to cutaneous malignant melanoma 
(Dieckhues et al., 1979; Pollack and Livingston, 1985), whereas HLA-B40 and the Class II alleles HLA-DR11 
and -DQ7 were related to local recurrences. It was suggested that Class II genes influence cytokine 
production and thus influence local immune responses against metastases (Lee et al., 2002). In uveal 
melanoma, studies failed to show that HLA antigens contributed to an increased genetic susceptibility, 
but this does not exclude an important role for HLA antigens in immune surveillance against uveal 
melanoma and their metastases (Maat et al., 2006). Increased expression of HLA Class I as well as of 
Class II expression of the primary tumor carries an unfavorable prognosis, occurs more frequently in 
epithelioid tumors, and is associated with an increased number of CD3+ and CD4+ T-lymphocytes, as 
well as with an increased density of CD11b+ macrophages (de Waard-Siebinga et al., 1996; Maat et al., 
2008b). 
In order to increase the understanding of prognostic factors and behavior of uveal melanomas, 
cytogenetic, genetic and epigenetic markers as prognostic factors will be discussed in the next 
paragraph.
Genetics and epigenetics
Genetic and cytogenetic factors
From the late eighties on, several reports on the cytogenetic analysis of uveal melanoma have been 
published. The first molecular abnormalities described in uveal melanoma were gross chromosomal 
alterations in cultured uveal melanoma cells of chromosomes 3, 6 and 8 in a series of six posterior uveal 
melanomas (Sisley et al., 1990). Gain or loss of chromosomal material in chromosomes 3, 6, and 8, has been 
validated in primary uveal melanomas and are associated with prognostic outcome (Seddon et al., 1983b; 
Horsman et al., 1990; Prescher et al., 1990; Sisley et al., 1990;). The most frequent change, in approximately 





1990). Loss of one of the 2 copies of chromosome 3, i.e. monosomy 3 or -3, was one of the first, and still 
the most important, chromosomal alteration that has been described in uveal melanoma. Follow-up of 
patients having tumors with monosomy 3 showed that 57% developed metastases within 3 years, in 
contrast to patients with tumors that retained both copies of chromosome 3, who only rarely developed 
metastases (Prescher et al., 1990). Furthermore, monosomy 3 is correlated with other poor prognostic 
indicators such as larger tumor diameter, epithelioid cell type, extravascular matrix patterns and ciliary 
body involvement (Scholes et al., 2003; Ehlers and Harbour, 2006). However, till today it remains unclear 
how monosomy 3 contributes causally to uveal melanoma development and progression. Another 
common chromosome abnormality found in uveal melanoma is gain of extra copies of chromosome 
8q (isochromosome 8q or i8q) (Horsman et al., 1990; Aalto et al., 2001). Gain of chromosomal arm 8q is 
found in approximately 40-65% of the tumors and is almost as strongly linked with metastatic disease 
as is monosomy 3 (Horsman et al., 1990; Speicher et al., 1994; Ghazvini et al., 1996; Sisley et al., 1997). 
Consequently, they are often found together (Horsman and White, 1993; White et al., 1998; Damato 
et al., 2007). Also other chromosome changes such as loss of chromosome 1p, gain of 6p and loss of 
chromosome 6q, seem to be involved in survival (Prescher et al., 1990; Aalto et al., 2001; Hausler et al., 
2005). Furthermore, loss of chromosome 2, 21 and the sex chromosomes have been reported (Mukai and 
Dryja, 1986; Griffin et al., 1988; Horsman et al., 1990; Prescher et al., 1990; Sisley et al., 1990; Sisley et al., 1992; 
Wiltshire et al., 1993; Singh et al., 1994; Prescher et al., 1994; Tschentscher et al., 2000).
Gene-expression profiling
As shown, the chromosomal aberrations found in uveal melanoma on chromosome 3, 6 and 8q have 
been linked to metastatic death (Prescher et al., 1996; Sisley et al., 1997). For many years, it remained 
unclear whether these chromosomal aberrations are simply markers of tumor progression or whether 
these are associated with deregulation of specific genes (Loercher and Harbour, 2003). In recent years, 
there have been important breakthroughs in unraveling the molecular basis of uveal melanoma and its 
tendency to metastatic disease. Recently, it was shown that primary uveal melanomas cluster into two 
distinct molecular classes based on gene-expression profiles of roughly equal proportions (Onken et al., 
2004). Tumors with the class I gene expression profile rarely metastasize, whereas those with the class 
II gene expression profile have a very high rate of metastasis (Onken et al., 2004; Petrausch et al., 2007; 
Worley et al., 2007; van Gils et al., 2008). Genes that discriminate class I (low-grade) from class 2 (high-
grade) include highly significant clusters of down-regulated genes on chromosome 3 and up-regulated 
genes on chromosome 8q and provide insights into the mechanism underlying metastasis (van Gils et 
al., 2008). Biological function annotations of the most differentiating genes included cell communication, 
development, cell growth, cell motility and cell death. Most of the developmental genes have been 
implicated in neural crest development, which gives rise to melanocytes. The expression profile of class I 
tumors is only slightly different than of normal uveal melanocytes, suggesting that relatively few genetic 
changes have occurred. In contrast, the class II expression profile is very different from melanocytes and 




Mutational deregulation of the cell cycle is a hallmark of tumorigenesis (Hanahan and Weinberg, 
2000). The protein product of the Retinoblastoma gene (Rb) plays a central role as inhibitor of cellular 
proliferation (Bartek et al., 1997), so inactivation of the Rb gene leads to unregulated proliferation. Despite 
the absence of mutations of this gene in uveal melanoma, Rb is frequently mutated in many different 
types of cancer, such as retinoblastoma. It has been known for several years that, in uveal melanoma, 
disruption of the retinoblastoma tumor-suppressor pathway is common by hyperphosphorylation of 
Rb, allowing cells to re-enter the cell cycle (Brantley Jr. and Harbour, 2000a; Brantley Jr. and Harbour, 
2000b). Progression of cells through the G1 phase of the cell-cycle is stimulated by the association of 
D-type cyclins with cyclin-dependent kinases (CDK’s) that phosphorylate Rb (Sherr, 1993). Normally, Rb 
inhibits proliferation by arresting cells in the G1 phase of the cell cycle. For cell division to occur, Rb is 
hyperphosphorylated and inactivated by CDK’s that interact with their cyclin partners to form active 
kinase complexes. CDK’s are in turn restrained by inhibitors such as p16, which block CDK4/6 and allow 
hypophosphorylated Rb to accumulate. The result of these interactions is a tightly regulated pathway 
that allows cell division only under appropriate physiological circumstances (Brantley Jr. and Harbour, 
2000b). 
The gene that encodes for p16 (CDKN2A) has been identified as an inhibitor of the cyclin D/CDK complex 
(Serrano et al., 1993). The inhibitory activity of p16 is restricted to the cyclin D-CDK4 and cyclin D-CDK6 
kinases and results in cell cycle control at the G1-S restriction point (Mao et al., 1995; van der Velden et 
al., 2001). CDKN2A is commonly inactivated in a wide range of malignancies (Sharpless and DePinho, 
1999), but CDKN2A germ-line mutations are uniquely associated with familial cutaneous melanoma 
(Hussussian et al., 1994; Gruis et al., 1995; Harland et al., 1997). Whereas CDKN2A is the main target of 
inactivation in cutaneous melanoma, mutation screening and deletion mapping did not reveal such a 
role for CDKN2A in uveal melanoma (Merbs and Sidransky, 1999). Analysis of uveal melanoma cell lines 
and primary tumors revealed promoter methylation of CDKN2A as an alternative mechanism for tumor 
suppressor-gene inactivation (van der Velden et al., 2001). Furthermore, recent analysis revealed that 
other important genes such as TIMP3 and RASSF1a are also inactivated by methylation, suggesting that 
epigenetic events are a common phenomenon in uveal melanoma.
Epigenetics
Epigenetics is a term in biology used to refer to chromatin and DNA modifications of unicellular and 
multicellular organisms that are stable over rounds of cell division but do not involve changes in the 
underlying DNA sequence of the organism (Bird, 2007). These epigenetic changes play a role in the 
process of cellular differentiation, allowing cells to stably maintain different characteristics despite 
containing the same genomic material. DNA methylation in human cells denotes the covalent addition 
of a methyl group to the 5’ position of the cytosine ring on the DNA. In vertebrates, it typically occurs at 





in the DNA sequence). Attachment of such a methyl group to a cytosine results in conversion to a 
5-methylcytosine, which process is catalyzed by a group of enzymes called DNA methyltransferases. CpG 
sites are uncommon in vertebrate genomes but are often found at higher density near gene promoters 
where they are collectively referred to as CpG islands. The methylation state of these CpG sites can have a 
major impact on gene activity and expression. Under physiological conditions, methylation is associated 
with the distinct, but mechanistically related, process of X chromosome inactivation (silencing of one X 
chromosome but not the other in all human female cells), genomic imprinting (silencing or activation of 
a gene inherited from one parent or the other) or transcriptional silencing of repetitive DNA sequences 
(Wolf and Migeon, 1982; Barlow, 1995; Kochanek et al., 1995).
Alterations of gene expression may also be obtained during carcinogenesis through a process called 
de novo methylation of CpG islands in gene promoters (Bestor and Verdine, 1994; Okano et al., 1998). 
Changes in methylation of the promoter or the first exon may have enormous effects on the expression 
of tumor-suppressor genes or proto-oncogenes. Hypermethylation of promoter regions may cause 
transcriptional silencing of tumor suppressor genes. On the other hand, hypomethylation of regulatory 
DNA sequences might activate transcription of proto-oncogenes, as well as genes encoding proteins 
involved in genomic instability or metastatic behavior. In cancer research, DNA methylation is often 
regarded as the epigenetic mechanism that blocks gene expression. Methylation of promoter-
associated CpG islands has recently emerged as an important epigenetic mechanism leading to the 
transcriptional silencing or downregulation of tumor-suppressor genes in cancer development (Jones 
and Baylin, 2002). Methylation of tumor-suppressor genes is now commonly analyzed in tumors and 
even rivals mutation and deletion as the main mechanism in tumor development in certain tumors 
(Robertson, 2005). For example, in cutaneous melanoma, at least 50 genes have been identified to date 
to be silenced during disease development and progression by promoter hypermethylation (van Doorn 
et al. 2005; Rothhammer and Bosserhoff, 2007). Although numerous studies have addressed the genetic 
events involved in the development of uveal melanoma, only a few have focused on the epigenetic 
events that occur during tumorigenesis (see next paragraph).
MAPK Pathway activation
Activation of the RAS-RAF-MEK-ERK, or mitogen-activated protein kinase (MAPK) pathway, is crucial 
for the development of melanocytic neoplasia (Cohen et al., 2002). This pathway is perhaps the most 
common signaling pathway affected by early oncogenic mutations. Mutations in B-RAF, N-RAS, H-RAS 
and KIT lead to constitutive activation of this pathway and have been associated with many different 
types of cancer (Goding, 2000; Reddy et al., 2003). Constitutive activation of the RAF-MEK-ERK pathway 
stimulates the transcription of pro-proliferative genes, such as CCND1, JUN and MYC (Dahl and Guldberg, 
2007; McCubrey et al., 2007)
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In cutaneous melanoma, activation of this pathway has been shown to occur by a variety of mechanisms, 
including autocrine growth factor stimulation and mutation of the N-RAS (20% of cases) and B-RAF (60% 
of cases) genes (van Elsas et al., 1995; Davies et al., 2002; Satyamoorthy et al., 2003). All B-RAF mutations 
in cutaneous pigmented neoplasms occur within the kinase domain, and the most frequently found 
mutation in B-RAF consists of a 1799T—› A transversion in exon 15, although various other mutations 
have been described as well (Brose et al., 2002; Davies et al., 2002; Pollock and Meltzer, 2002; Satyamoorthy 
et al., 2003). This T1799A mutation is located in the serine/threonine kinase domain of B-RAF, resulting in 
a valine-to-glutamic acid substitution at position 600 (B-RAF V600E), leading to a constitutive activation 
of proliferation signaling (Zhang and Guan, 2000; Wellbrock et al., 2004). Interestingly, B-RAF mutations 
occur very early in cutaneous malignant melanoma, and are even present in benign and pre-malignant 
nevi (Davies et al., 2002; Pollock and Meltzer, 2002).
Since cutaneous malignant melanoma and uveal melanoma both arise from neural-crest derived 
melanocytes, the MAPK pathway came also under attention in uveal melanoma research (Mooy et al., 
1991; Soparker et al., 1993; Cohen et al., 2003; Cruz, III et al., 2003; Edmunds et al., 2003; Rimoldi et al., 
2003; Weber et al., 2003; Kilic et al., 2004; Zuidervaart et al., 2005; Calipel et al., 2006). Activation of the 
MAPK pathway has been reported in uveal melanoma, although it only rarely occurs through mutations 
in B-RAF or RAS (Zuidervaart et al., 2005). Recently, others and we have found that uveal melanoma 
is heterogeneous and that, with more sensitive techniques, the percentage of mutant B-RAF-positive 
uveal melanomas may be slightly higher (Janssen et al., 2008; Maat et al., 2008a). The lack of mutations 
in the majority of cells is in contrast with immunohistochemistry and western blot analysis, which 
have shown activation of ERK1/2 in most uveal melanomas (Rimoldi et al., 2003; Weber et al., 2003; 
Zuidervaart et al., 2005). Furthermore, the RAF-MEK-ERK pathway target CCND1, which encodes cyclin 
D1, is over-expressed in most uveal melanomas (Brantley Jr. and Harbour, 2000a; Coupland et al., 2000), 
and leads to hyperphosphorylation and inactivation of the retinoblastoma tumor suppressor (Rb) in 
uveal melanoma (Brantley Jr. and Harbour, 2000b; Delston and Harbour, 2006). CCND1 overexpression 
is likely transcriptionally mediated by activation of the RAF-MEK-ERK pathway, since amplification of Rb 
in uveal melanoma is rare (Glatz-Krieger et al., 2006). Nevertheless, the pharmacological inhibition of 
MAPK/ERK kinases 1 and 2 (MEK1/2) and the genetic targeting of BRAF with siRNA resulted in a reduced 
proliferation of uveal melanoma cell lines (Lefevre et al., 2004; Calipel et al., 2006). This indicates that 
although mutations are absent, the RAS-RAF-MEK-ERK pathway is essential for uveal melanoma growth 
and suggests that an upstream factor is involved in autonomous uveal melanoma proliferation. Recently, 







Uveal melanoma is the most common malignancy of the eye in adults and it is the second most common 
form of melanoma after cutaneous melanoma (Mooy and De Jong, 1996; Bergman et al., 2003; Singh 
and Topham, 2003a). The identification of patients who have a high risk of developing metastases would 
allow the possibility of providing adjuvant therapies to prevent metastases once such therapies have 
been developed or may allow close monitoring for the presence of liver metastases in such individuals, 
who may then be offered liver resection surgery or chemotherapy at an early stage (Missotten and 
Keunen, 2004). The application of fluorescence in-situ hybridization (FISH) on transvitreal fine-needle 
aspiration biopsies (FNAB’s) is thought to be a reliable method for assaying genetic parameters such as 
chromosome 3 loss (Naus et al., 2002). However, this is based on the assumption that this chromosomal 
abnormality is distributed homogeneously throughout the tumor. In chapter 2 we investigate the 
distribution of monosomy 3 in primary uveal melanoma by fluorescence in-situ hybridization and 
show that uveal melanomas can be heterogeneous for the number of copies of chromosome 3. In 
chapter 3 we investigated whether, besides for chromosomal aberrations, any evidence can be found 
for heterogeneity in the regulation of tumor-suppressor genes. The tumor-suppressor gene RASSF1a, 
which is located on chromosome 3p21.3, has been shown to be inactivated by hypermethylation in 
several human malignancies, including cutaneous melanoma (Spugnardi et al., 2003; Kang et al., 2004; 
Yeo et al., 2005; Fukasawa et al., 2006). Recently, a segregation study in families with uveal and cutaneous 
melanoma identified 9q21 as a potential locus harboring a tumor-suppressor gene. One of the genes in 
this area, RASEF, was then analyzed as a candidate tumor-suppressor gene, but lack of point mutations 
and copy number changes could not confirm this. In chapter 4, we studied whether in uveal melanoma, 
the RASEF gene was affected by mutations or gene silencing due to promoter methylation.
The RAS-RAF-MEK-ERK pathway is involved in the balance between melanocyte proliferation and 
differentiation. In cutaneous and uveal melanoma, the same pathway is constitutively activated 
and related to tumor growth and survival. Whereas mutant B-RAF and N-RAS are responsible for the 
activation of the RAS-RAF-MEK-ERK pathway in most cutaneous melanoma, mutations in these genes 
are usually absent in uveal melanoma. Nowadays, an assay with increased potential to identify mutations 
is available. In chapter 5, we set out to reanalyze uveal melanoma cell lines and primary uveal melanomas 
for B-RAF mutations by using pyrophosphorolysis-activated polymerization. In chapter 6 we set out to 
explore the RAS-RAF-MEK-ERK pathway by using mitogen-activated protein kinase profiling and tyrosine 
kinase arrays.
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PURPOSE. The detection of monosomy 3 in uveal melanomas has repeatedly been associated 
with adverse outcome. Fine-needle aspiration biopsy is being used to detect monosomy 3 in these 
tumors, based on the assumption that this chromosomal abnormality is distributed homogeneously 
throughout the tumor. The purpose of this study is to study the distribution of monosomy 3 in primary 
uveal melanoma by fluorescence in situ hybridization (FISH).
METHODS. We studied 50 enucleated eyes with uveal melanoma. In all 50 tumors we performed 
cytogenetic analysis and FISH using a DNA-specific probe for the centromere region of chromosome 
3 on cultured tumor cells. In addition, the percentage of tumor cells with monosomy 3 was assessed 
by FISH on nuclei, isolated from paraffin-embedded tissue and compared to results of FISH on regular 
histology sections of the paraffin-embedded tissue.
RESULTS. Combining karyotyping and FISH on cultured cells identified monosomy 3 in 19 (38%) of 
50 tumors, whereas FISH on nuclei isolated from paraffin-embedded tissue showed 31 (62%) of 50 as 
having monosomy for chromosome 3. FISH analysis on paraffin sections showed tumor heterogeneity 
for copy number of chromosome 3 in at least 7 cases.
CONCLUSIONS. FISH analysis on paraffin sections shows that heterogeneity of monosomy of 
chromosome 3 is a frequent phenomenon in uveal melanoma. FISH on nuclei isolated from paraffin-
embedded tissue identifies a higher frequency of monosomy 3 than the traditional combination of 
karyotyping and FISH on cultured uveal melanoma cells. The practice of assigning patients to risk 
categories based on fine-needle aspiration biopsy samples from primary uveal melanoma may be 
subject to error based on the heterogeneous distribution of monosomy 3 in these tumors.





Uveal melanoma is the most common malignancy of the eye in adults and it is the second most 
common form of melanoma after cutaneous melanoma (Mooy and de Jong, 1996; Bergman et al., 2003; 
Singh and Topham, 2003). Several prognostic factors based on clinical and histologic features have been 
correlated with an unfavorable prognosis in patients with uveal melanoma: among these parameters 
are tumor size, ciliary body involvement, the presence of epithelioid cells, and vasculogenic mimicry 
(Mooy and de Jong, 1996). The identification of patients who have a high risk of developing metastases 
would allow the possibility of providing adjuvant immunotherapy or chemotherapy to prevent 
metastases once such therapies have been developed or may allow close monitoring for the presence 
of liver metastases in such individuals, who may then be offered liver resection surgery at an early stage 
(Missotten and Keunen, 2004). Nonrandom chromosome abnormalities, such as variation in the short 
arm of chromosome 1, and gain or loss of chromosomal material in chromosomes 3, 6, and 8, have been 
detected in uveal melanomas and are associated with metastasis (Sisley et al., 1990; Naus et al., 2001). The 
most frequent change, in approximately 50% of all uveal melanomas, is the loss of 1 copy, or monosomy, 
of chromosome 3 (Horsman et al., 1990; Sisley et al., 1990). Follow-up of patients having tumors with 
monosomy 3 showed that 57% developed metastases within 3 years, in contrast to patients with tumors 
that retained both copies of chromosome 3, who only rarely developed metastases (Prescher et al., 1996). 
The application of fluorescence in situ hybridization (FISH) on transvitreal fine-needle aspiration biopsies 
(FNABs) is thought to be a reliable method for assaying genetic parameters such as chromosome 3 
loss (Naus et al., 2002). This approach is based in part on the assumption that uveal melanomas with or 
without loss of 1 copy of chromosome 3 represent 2 distinct entities: in monosomy 3-positive tumors, 
the chromosomal abnormality will be detected in every cell and is thus susceptible to identification by 
random sampling by the FNAB technique.
To detect monosomy 3, we performed standard cytogenetic analysis by karyotyping and FISH on cultured 
uveal melanoma cells obtained after enucleation. We subsequently also analyzed FISH on paraffin 
sections and observed heterogeneity within tumors. However, in many tumors, the application of this 
technique was limited by the presence of necrotic areas and heavy pigmentation. We therefore analyzed 
monosomy 3 by FISH technique on nuclei isolated from paraffin-embedded tissue. This technique can 
provide additional information about clonal expansion of cells with monosomy of chromosome 3 and 
about tumor heterogeneity for this specific chromosomal aberration. The results were compared with 




Patients and Tissue Samples
Fresh material and formalin-fixed, paraffin-embedded specimens from 50 patients with uveal melanoma 
were obtained from tumors that were enucleated during the period 1999 through 2004 at the Leiden 
University Medical Center from which enough material was present for cytogenetic analysis. After 
enucleation, tumor material for cytogenetic testing was obtained immediately after the globe had 
been opened. Each tumor sample was further processed for conventional histopathologic diagnosis. 
The research protocol followed the tenets of the Declaration of Helsinki (World Medical Association 
Declaration of Helsinki 1964; Ethical principles for medical research involving human subjects). 
Karyotyping and Interphase FISH on Cultured Cells 
After enucleation, a small part of each tumor was removed and sent out for cell culture. Following 
mechanical dissection of the tumor biopsy, cells were washed and placed into 1 flask with RPMI 1640 (15% 
fetal bovine serum [Invitrogen, Breda, The Netherlands]) medium and another flask with Amniochrome II 
(Cambrix Bio Science, Verviers, Belgium). The flasks were cultured at 37°C with 5% CO2 for up to 4 weeks 
and harvested, according to standard protocols, when at least 75% of the surface was covered with cells 
(after a mean of 18 days; SD 9.4 days). When cell culturing was successful, conventional karyotyping 
and FISH with a DNA-specific probe was performed, to determine the presence of chromosome 3 
changes according to established methods (Dauwerse et al., 1992). Probe CEN 3 (Vysis, Des Plaines, 
Ill) was used for all FISH experiments. The cutoff value for monosomy 3 was 10% for the cultured cells. 
Two independent observers assessed all evaluations and scores, each without knowledge of the results 
obtained by the other investigator, to ensure accuracy of quantification of the slides. In the case of a 
difference, consensus was reached during a simultaneous session. Cytogenetic analysis was performed 
on GTG-banded (G-banding with Giemsa and trypsin) metaphases. In the case of a normal karyotype, at 
least 20 metaphases were analyzed. When an abnormal clone was detected in the first 10 karyotyped 
cells, no further analysis was performed; when 3 cells with loss of 1 copy of chromosome 3 were 
observed, monosomy 3 was identified. 
Interphase FISH on Paraffin-Embedded Tissue Sections
We performed interphase FISH on paraffin-embedded sections as described previously by Haralambieva 
et al. (Haralambieva et al., 2002). In brief, 4-µm paraffin-embedded sections, mounted on coated 
slides, were deparaffinized and rehydrated. Slides were next exposed under pressure at 100°C in Tris/
ethylenediaminetetraacetic acid buffer solution, and then the slides were washed in standard saline 
citrate buffer solution. RNase (New England BioLabs, Ipswich, Mass) treatment was performed followed 
by enzymatic digestion with pepsin. Thereafter, tissue samples were washed with phosphate- buffered 
saline, dehydrated in ethanol, and air-dried. DNA probe CEP3 SpectrumOrange: CEN 3, specific for the 
centromere region of human chromosome 3 (band region 3p11.1q11.1), was used for hybridization 




according to the manufacturer’s protocol. The denaturation step was performed at 80°C for 12 minutes. 
DAPI (4’-6-diamidino-2-phenylindole) staining was performed to distinguish between tumor areas and 
fields containing normal cells in the sections.
Interphase FISH on Nuclei Isolated From Paraffin-Embedded Tissue
The protocol for interphase FISH on nuclei isolated from 50- µm paraffin-embedded tissue sections 
was adapted from the procedure for hybridization on paraffin sections as described by Haralambieva 
et al. (Haralambieva et al., 2002) and optimized by Jordanova et al. (Jordanova et al., 2002). In brief, 
after enzymatic digestion with pepsin and 2 additional washing steps with phosphate-buffered saline, 
cells were filtered through a 70-µm-pore-size nylon filter (Verseidag-Industrietextilen GmbH, Kempen, 
Germany). Cells were fixed with methanol–acetic acid (3:1). Prior to making cytospins, cell density was 
determined in a 5-µL methanol–acetic acid suspension to ensure that at least 400 to 500 nuclei were 
present in each cytospins (Vaandrager et al., 2000). The slides were air dried and used for hybridization. 
For hybridization, the same DNA-specific probe was used as for the paraffin embedded tissue sections. 
Three tonsils of healthy individuals were used as controls. The tonsil sections were treated in exactly the 
same manner as the patient samples. The cutoff level was set at the mean of these controls plus 3 times 
the standard deviation and was calculated as 5% for detecting monosomy 3.
Two independent observers assessed all slides, each without knowledge of the results obtained by the 
other investigator, to ensure accuracy of quantification of the slides. Scoring results corresponded in 
47 cases; for 3 cases with values around the cutoff value (ID UM04, UM19, and UM20) consensus could 
be reached during a simultaneous session. Slides were analyzed using a Leica DMRXA fluorescence 
microscope (Leica Imaging Systems, Cambridge, United Kingdom). Image capture was performed 
by a monochrome CCD camera (COHU, San Diego, Calif ) attached to the fluorescence microscope 
and Leica Q-FISH software (Leica). The 2 observers each analyzed 100 cells, 200 interphase nuclei in 




In this study a substantial proportion of medium-sized and large-sized tumors (COMS Report No. 4, 1997, 
COMS Report No. 20, 2003) (48% and 50% of the 50 cases, respectively) were included, as relatively small 
tumors were treated by alternatives to enucleation such as radiation therapy. The average age of the 23 
female and 27 male patients was 59 years (range, 24–85 years).
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Karyotyping and FISH on Cultured Cells 
Conventional karyotyping was performed on cell cultures of 50 choroidal melanomas and was 
unsuccessful in 4 tumors; 1 failure could be attributed to a technical problem. We did not identify 
significant differences in prognostic characteristics (such as tumor thickness or location) between the 4 
unsuccessful tumors and the cases that were technically successful. In 2 additional cases, no conclusion 
could be reached regarding the absence or presence of monosomy 3, as less than 20 karyotypes could be 
analyzed. Karyotyping showed unambiguous monosomy 3 in 15 of 44 evaluable cases (Table 2.1). FISH 
analysis was also performed on cultured cells from choroidal melanomas. However, it was not performed 
in 4 cases that had already been shown to have monosomy 3 and in 2 cases for logistical reasons. The 
technique failed in 3 cases because of electrical power failure. In the 4 tumors in which karyotyping had 
not been successful, FISH analysis was conclusive. Of the 41 evaluable cases, FISH showed 1 copy of 
chromosome 3 in 15 cell cultures and identified 25 cases that carried both copies of chromosome 3. By 
combining karyotyping with FISH data on the cultured cells in all 50 cases, monosomy 3 was detected 
in 19 cases (38%), whereas 29 cases (58%) were found to be diploid for chromosome 3 and 2 tumors (4% 
of cases) showed 3 copies of chromosome 3 (Table 2.1).
Table 2.1. Data on Karyotyping and Fluorescence In Situ Hybridization (FISH) Analyses for 50 Tumors, Analyzed for 
Chromosome 3 Aberrations by Karyotyping and FISH on Cultured Cells and by FISH on Nuclei Isolated From Paraffin-
Embedded Tissue. Percentages indicate the amount of cells with 2 (disomy), 1 (monosomy), 3 (trisomy), or more 
signals for chromosome 3. D indicates disomy; M, monosomy; T, trisomy; 4, >3 signals; F, failed; NP, not performed; 
and U, unclear.




FISH FISH    D / M / T / 4  (%) ID
Karyo-
typing
FISH FISH D / M / T / 4  (%)
UM01 D D D 98 / 00 / 01 / 01 UM26 D T M 70 / 29 / 01
UM02 D D D 98 / 01 / 01 UM27 D M M 60 / 40
UM03 D D D 96 / 01 / 02 / 01 UM28 D M M 41 / 58 / 01
UM04 D D D 96 / 03 / 01 UM29 D M M 37 / 63
UM05 D D D 96 / 01 / 02 UM30 D M M 31 / 69
UM06 D D D 95 / 02 / 02 / 01 UM31 D NP M 42 / 57
UM07 D D D 95 / 01 / 03 / 01 UM32 F D M 83 / 17
UM08 D D D 95 / 01 / 01 / 03 UM33 F D M 39 / 60 / 01
UM09 D D D 94 / 01/ 02 / 03 UM34 U D M 47 / 52 / 01 
UM10 D D D 93 / 00 / 03 / 04 UM35 M NP M 72 / 24 / 04
UM11 D D D 93 / 01 / 04 / 02 UM36 M NP M 69 / 30 / 01
UM12 D D D 92 / 01 / 05 / 02 UM37 M NP M 57 / 42 / 01
UM13 D D D 88 / 01 / 04 / 07 UM38 M M M 58 / 41 / 01
UM14 D F D 98 / 01 / 01 UM39 M M M 54 / 46









FISH FISH    D / M / T / 4  (%) ID
Karyo-
typing
FISH FISH D / M / T / 4  (%)
UM15 D F D 97 / 01 / 02 UM40 M M M 43 / 57
UM16 D F D 97 / 00 / 01 / 02 UM41 M M M 42 / 58
UM17 F D D 88 / 03 / 08 / 01 UM42 M M M 40 / 60
UM18 F D D 96 / 02 / 02 UM43 M M M 40 / 60
UM19 U D D 96 / 04 UM44 M M M 37 / 63
UM20 D D M 89 / 07 / 01 / 03 UM45 M M M 36 / 64
UM21 D D M 73 / 27 UM46 M M M 22 / 78
UM22 D D M 60 / 40 UM47 M M M 18 / 82
UM23 D D M 60 / 40 UM48 M M M 18 / 82
UM24 D D M 38 / 62 UM49 M NP M 06 / 94
UM25 D D M 36 / 64 UM50 T NP M 49 / 51
Interphase FISH on Paraffin-Embedded Tissue Sections
In situ hybridization was performed on paraffin sections of all 50 choroidal melanomas. Primary uveal 
melanomas typically do not contain significant amounts of stromal elements (Lin et al., 2005) so the 
detection of signals on histologic preparations is likely to originate from tumor cells. Furthermore, 
the nuclei of tumor cells are significantly larger than in fibroblasts or endothelial cells, thus ensuring 
that the signals counted in this study originated from tumor cells. However, heavy pigmentation in 
histologic sections made it difficult to evaluate the FISH preparations. Another problem is that the use of 
4-µm-thick sections of paraffin tissue, in which nuclei are cut through, results in different hybridization 
patterns and leads to difficulties in interpreting these sections in a diagnostic setting as described earlier 
(Hensen et al., 2004) (Figure 2.1). Still, in 7 tumors without heavy pigmentation, tumor heterogeneity for 
chromosome 3 was clearly observed and these tumors should therefore be considered as being partly 
disomy and partly monosomy for chromosome 3 (Figure 2.2, A through D). In 18 tumors, 2 hybridization 
signals were found in almost all cells, suggesting the presence of 2 copies of chromosome 3 in each cell; 
in 8 cases, 1 or no signals was seen in almost every cell, which implies the homogeneous presence of a 




Figure 2.1. Schematic representation of nuclei with different patterns of hybridization signals in tissue sections. As 
tissue sections cut through nuclei at different levels, more hybridization signal patterns can be seen in tissue sections 
than when using isolated nuclei. When 2 hybridization signals are observed in a cell, the presence of 2 copies of 
chromosome 3 is assumed; if 1 or no signal is observed, this implies the presence of a cell with monosomy 3.
Figure 2.2. A, Hematoxylin-eosin staining of a uveal melanoma (whole mount). B, Area indicated in A that 
shows heterogeneity for chromosome 3 by fluorescence in situ hybridization (FISH) analysis on a paraffin section 
(original magnification x400). The red areas are positively stained pigment deposits. C, Typical hybridization pattern 
representative of disomy of chromosome 3 in the area indicated in B (original magnification x1000). D, Typical 
hybridization pattern representative of monosomy of chromosome 3 in the area indicated in B (original magnification 
x1000). A through D are derived from the same uveal melanoma.




Interphase FISH on Nuclei Isolated From Paraffin-Embedded Tissue
As interpretation of FISH signals on paraffin sections was difficult, we identified the number of copies of 
chromosome 3 on nuclei isolated from paraffin tissue. This technique was successful in all cases. Signals 
were bright and intense and easily recognizable (Figure 2.3). With a threshold value of 5% (as based on 
the normal controls), 19 uveal melanomas (38%) were categorized as disomic for chromosome 3 and 
31 (62%) as having monosomy for chromosome 3. Twelve of the tumors that showed monosomy 3 on 
isolated nuclei had not been recognized by the combination of karyotyping and FISH on cultured cells 
(Figure 2.4). In a minor percentage of nuclei, more than 2 signals were observed, which is the result of 
fragmentation of the centromere signal and does not reflect an aberration. A comparison of the data on 
isolated nuclei versus the chromosome analysis on cultured cells is provided in the Table 2.1. Although 
the analysis on cultured cells led to the identification of monosomy 3 in 38% of cases, FISH analysis on 
isolated nuclei identified 62% of uveal melanoma as having monosomy 3.
Figure 2.3. Example of nuclei isolated from paraffin tissue of a uveal melanoma after hybridization for the centromere 
of chromosome 3. Two nuclei show 2 signals, indicating disomy of chromosome 3. The nucleus at the bottom shows 
1 signal, indicative for loss of 1 copy of chromosome 3 (original magnification x1000).
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Figure 2.4. Fifty uveal melanomas were studied for the presence of numerical aberrations of chromosome 3. 
Combining karyotyping and fluorescence in situ hybridization (FISH) analysis on short-term uveal melanoma cell 
cultures, 19, 29, and 2 tumors were identified as having monosomy 3, disomy 3, and trisomy 3, respectively. Using 
FISH analysis on nuclei isolated from paraffin-embedded tissue, 31 tumors (62%) possessed monosomy 3.
Comment
Genetic imbalance for chromosome 3 represents a significant risk factor for metastatic disease and 
reduced survival in patients with primary uveal melanoma (Prescher et al., 1996). Clinically significant 
genetic imbalances can occur as a result of a single loss of chromosome 3 with single or multiple losses or 
gains of other chromosomes, such as of chromosome 1 (Kilic et al., 2005). Conversely, the absence of any 
genetic imbalance is associated with a favorable prognosis. Monosomy 3 is the most reliable cytogenetic 
marker identified to date. Tumors that contain 2 copies of chromosome 3 rarely metastasize, whereas 57% 
of patients with a primary uveal melanoma that showed loss of 1 chromosome 3 developed metastasis 
within 3 years, most commonly to the liver (Prescher et al., 1996). The ability to identify those individuals 
at high risk for metastases may allow these patients to be monitored closely for the development of liver 
metastases so they can be offered adjuvant chemotherapy or liver resection surgery at an early stage 
(Missotten and Keunen, 2004; Kodjikian et al., 2005). As showed by Hoglund et al, (Hoglund et al., 2004) 
the imbalance in the number of copies of chromosome 3 may represent a starting point of karyotypic 
evolution. Theoretically, this karyotypic evolution may represent the initial event of oncogenesis and 
lay the basis of tumor formation. On the other hand, loss of chromosome 3 may be a late clonal event, 
which will occur when the tumor has already grown out, thus leading to heterogeneity with regard to 
the number of copies of chromosome 3. Studying chromosome 3 in a clinical setting is important in 
determining the patient’s prognosis. As we show here, detection of monosomy 3 is possible in uveal 




melanoma cell cultures after enucleation, but concerns about normal cell overgrowth in long-term cell 
cultures are unmistakably realistic. The fastest manner to detect monosomy 3 with the smallest number 
of artifacts would be to study only the number of copies of chromosome 3 using FISH on fresh tissue. 
Our observations regarding FISH on paraffin sections indicate that some uveal melanomas show disomy 
3 and monosomy 3 in different areas within the same tumor. This suggests that clonal expansion of cells 
with loss of 1 copy of chromosome 3 is probably a secondary event in uveal melanoma, which may 
subsequently be associated with dissemination.
This puts patients with tumors containing monosomy 3 cells at high risk for metastatic disease, even 
if monosomy 3 only occurs in part of the tumor. Identification of high-risk patients by using FNABs on 
tumors that will only be treated locally and will not undergo enucleation is of major importance but 
is, however, still under debate. Recently, Midena et al. (Midena et al, 2006) showed that FISH analysis 
on trans-scleral FNABs can yield sufficient material for molecular cytogenetic analysis and that FNAB is 
a reliable and efficient technique that may be valuable in predicting the prognosis in individuals with 
uveal melanoma. Fine-needle aspiration biopsies, however, will only detect changes in cells in the area 
from which the FNAB is taken and they do not provide information about the number of copies of 
chromosome 3 outside that region. In 1985, Folberg et al. (Folberg et al., 1985) compared the standard 
deviation of the nucleolar area measured from FNABs with the standard deviation of the nucleolar area 
measured from the matched enucleation specimen and concluded that FNABs do not yield the same 
prognostic information as larger enucleation specimens and that FNABs may not be representative of 
the tumor. Naus et al. (Naus et al., 2002) indicated that the application of FISH to FNABs is a reliable 
method for assaying genetic prognostic parameters such as chromosome 3 loss and that statistical 
analysis showed a very good agreement between the FISH results from the biopsies and those from 
the main tumor. However, FNABs were performed ex vivo under ideal circumstances on relatively large 
tumors and the article did not describe how many samples were obtained from 1 tumor. As we show 
here, uveal melanomas can be heterogeneous for the number of copies of chromosome 3. This implies 
that when using FNABs, one may miss the cells with monosomy 3 if they occur only in low numbers. A 
negative test does not exclude the presence of monosomy 3 somewhere in the tumor.
Acknowledgements
We thank all patients for participating in this study and Pieter van der Velden, PhD, and Guy Missotten, 
MD, PhD, for critically reading the manuscript. This study was supported by grant RUL 2001-2472 from 




Bergman L, Seregard S, Nilsson B, et al. Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis 
Sci. 2003;44:3282–3287.
Collaborative Ocular Melanoma Study Group: Mortality in patients with small choroidal melanoma: COMS report No. 
4: Arch Ophthalmol. 1997;115: 886–893.
Collaborative Ocular Melanoma Study Group: Trends in size and treatment of recently diagnosed choroidal melanoma, 
1987–1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS 
report No. 20. Arch Ophthalmol. 2003;121:1156–1162.
Dauwerse JG, Jumelet EA, Wessels JW, et al. Extensive cross-homology between the long and the short arm of 
chromosome 16 may explain leukemic inversions and translocations. Blood. 1992;79:1299–1304.
Folberg R, Augsburger JJ, Gamel JW, Shields JA, Lang WR. Fine-needle aspirates of uveal melanomas and prognosis. 
Am J Ophthalmol. 1985;100:654–657.
Haralambieva E, Kleiverda K, Mason DY, Schuuring E, Kluin PM. Detection of three common translocation breakpoints 
in non-Hodgkin’s lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. 
J Pathol. 2002;198:163–170.
Hensen EF, Jordanova ES, van Minderhout IJ, et al. Somatic loss of maternal chromosome 11 causes parent-of-
origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene. 
2004;23:4076– 4083.
Hoglund M, Gisselsson D, Hansen GB, et al. Dissecting karyotypic patterns in malignant melanomas: temporal 
clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer. 2004;108:57–65.
Horsman DE, Sroka H, Rootman J, White VA. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet 
Cytogenet. 1990;45:249–253.
Jordanova ES, Riemersma SA, Philippo K, et al. Hemizygous deletions in the HLA region account for loss of 
heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. 
Genes Chromosomes Cancer. 2002;35:38–48.
Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased 
disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46:2253–2257.
Kodjikian L, Grange JD, Baldo S, et al. Prognostic factors of liver metastases from uveal melanoma. Graefes Arch Clin Exp 
Ophthalmol. 2005;243:985–993.
Lin AY, Maniotis AJ, Valyi-Nagy K, et al. Distinguishing fibrovascular septa from vasculogenic mimicry patterns. Arch 
Pathol Lab Med. 2005;129:884–892. 
Midena E, Bonaldi L, Parrozzani R, et al. In vivo detection of monosomy 3 in eyes with medium-sized uveal melanoma 
using transscleral fine needle aspiration biopsy. Eur J Ophthalmol. 2006;16:422–425.
Missotten GS, Keunen JE. Screening for uveal melanoma metastasis: literature review. Bull Soc Belge Ophtalmol. 
2004;13–22.
Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 1996;41:215–228.
Naus NC, van Drunen E, de Klein A, et al. Characterization of complex chromosomal abnormalities in uveal melanoma 
by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization. Genes 
Chromosomes Cancer. 2001;30:267–273.
Naus NC, Verhoeven AC, van Drunen E, et al. Detection of genetic prognostic markers in uveal melanoma biopsies 
using fluorescence in situ hybridization. Clin Cancer Res. 2002;8:534–539.
Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 
1996;347:1222–1225.
Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110:956–
961.
Sisley K, Rennie IG, Cottam DW, et al. Cytogenetic findings in six posterior uveal melanomas: involvement of 
chromosomes 3, 6, and 8. Genes Chromosomes Cancer. 1990;2:205–209.
Vaandrager JW, Schuuring E, Raap T, et al. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma 
using breakpoint-flanking probes. Genes Chromosomes Cancer. 2000;27:85–94.
Chapter 3
Epigenetic Inactivation of RASSF1a 
in Uveal Melanoma
Willem Maat,1 Pieter A. van der Velden,1,2 Coby Out-Luiting,2 Maria Plug,3 
Anita Dirks-Mulder,3 Martine J. Jager,1 and Nelleke A. Gruis2
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):486-90.
Departments of 1Ophthalmology and 2Dermatology, Leiden University Medical Center, Leiden, 
The Netherlands; and 3Hogeschool Leiden, Leiden, The Netherlands.




PURPOSE. The RAS association domain family 1 (RASSF1) gene is a tumor-suppressor gene located 
on chromosome 3p21.3. The alternative transcript (RASSF1a) has been shown to be inactivated by 
hypermethylation in several human malignancies, including breast, prostate, and lung cancer, and in 
cutaneous melanoma. The purpose of this study was to evaluate the methylation status of RASSF1a in 
human uveal melanoma.
METHODS. The methylation status of the RASSF1a promoter region was analyzed using PCR in 
combination with melting curve analysis, sequencing, and restriction enzyme analysis. Eleven human 
uveal melanoma cell lines, normal melanocytes, 39 archival frozen tumor specimens, and a metastatic 
lesion of untreated primary uveal melanoma were studied. In addition, whether RASSF1a methylation 
correlates with patient survival and development of metastatic disease was investigated.
RESULTS. RASSF1a promoter methylation was detected in 10 of the 11 (91%) cell lines, in 19 of the 38 
(50%) patients with primary uveal melanoma and in the metastatic lesion. A positive correlation was 
found between RASSF1a promoter methylation and development of metastatic disease (P = 0.041). 
A correlation with disease-free survival could not be established, but a positive trend was observed 
(P = 0.063).
CONCLUSIONS. These data show that RASSF1a methylation is a common epigenetic event in uveal 
melanoma development, potentially of clinical relevance. The presence of a methylated RASSF1a 
promoter region might therefore serve as a tumor marker and as a possible target for therapeutic 
intervention. 





Uveal melanoma is the most common primary intraocular neoplasm in adults. It accounts for 70% of all 
primary eye tumors and occurs at an annual incidence of 6 to 8 per million in white populations (Egan et 
al., 1988). Uveal melanoma develops without any obvious genetic or environmental predisposing factors 
(Hanahan and Weinberg, 2000). An effective starting point for the identification of genetic changes is to 
study the chromosomes involved in the progression and development of uveal melanoma. Cytogenetic 
studies have identified a number of chromosomal abnormalities in uveal melanoma, of which loss 
of chromosome 1p, gain of 6p and i8q, and loss of one copy of chromosome 3 (i.e., monosomy 3) 
commonly occur (Horsman et al., 1990, Prescher et al., 1990, Sisley et al., 1990, Naus et al., 2002, Kiliç et 
al., 2005). Monosomy 3 is highly correlated with decreased survival and metastatic disease (Prescher et 
al. 1996, White et al., 1998), suggesting the presence of a tumor suppressor gene (TSG) at this location. 
Despite this information, genetic analysis of this chromosome has not revealed specific TSGs as players 
in uveal melanoma pathogenesis. Alternatively, hypermethylation of promoter-associated CpG islands 
has recently emerged as an important epigenetic mechanism leading to the transcriptional silencing of 
TSGs in cancer development (Jones and Baylin, 2002), including the development of uveal melanoma 
(Van der Velden et al., 2002, Van der Velden et al., 2003, Van Dinten et al., 2005). Recent findings in other 
malignancies have identified the Ras association domain family 1 (RASSF1) gene, located on chromosome 
3p21.3, as an important regulator of cell proliferation (Dammann et al., 2000, Hamilton et al., 2005, Choi 
et al., 2006). Hypermethylation of the CpG island in the promoter region of a major alternative transcript 
of this gene, RASSF1a, occurs frequently in various carcinomas, including those of the breast, prostate, 
and lung, and in cutaneous malignant melanoma (Spugnardi et al., 2003, Kang et al., 2004, Yeo et al., 
2005, Fukasawa et al., 2006). In this study, we investigated RASSF1a gene hypermethylation in uveal 
melanoma. We demonstrated that RASSF1a methylation of its promoter CpG island in uveal melanoma 
cell lines and primary tumors is a common event. Furthermore, we showed a correlation between 
RASSF1a hypermethylation and the development of metastatic disease. Consequently, we postulated 
that the methylation of RASSF1a is a prognostic tumor marker for uveal melanoma and may serve as a 
potential target for therapeutic intervention.
Materials and methods
Cell Lines, Primary Uveal Melanoma Specimens, and the Metastatic Lesion
In total, 11 cell lines derived from primary uveal melanomas (92.1, OCM-1, OCM-3, OCM-8, Mel-202, Mel-
270, Mel-285, Mel-290) and uveal melanoma metastases (OMM-1, OMM-1.3, OMM-1.5) and a culture of 
normal uveal melanocytes (Mel-1a) were analyzed for promoter hypermethylation. Cell lines Mel-270, 
OMM-1.3, and OMM-1.5 represent a progression model because they were derived from a primary uveal 
melanoma and two of its liver metastases, respectively. All melanoma cell lines were cultured in RPMI 
1640 medium (Gibco, Paisley, Scotland) supplemented with 3 mM L-glutamine (Gibco), 2% penicillin/
streptomycin, and 10% FBS (Hyclone, Logan, UT). The melanocyte cell line (Mel-1a) was grown in F12 
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medium (Gibco) (Zuidervaart et al., 2003). All cell cultures were incubated at 37°C in a humidified 5% CO2 
atmosphere. Archival frozen tumor specimens of primary uveal melanoma came from 39 patients who 
attended the Leiden University Medical Center between 1988 and 1996. The metastatic lesion (adrenal 
gland metastasis) was derived from the patient with a primary uveal melanoma (tumor 31), from which 
cell line 92.1 was derived (Waard-Siebinga et al.,1995, Blom et al., 1997). All tumors were primary lesions 
with diameters greater than 12 mm and prominences greater than 6 mm; patients had not received 
any treatment before enucleation. The validity of the diagnosis, uveal melanoma, was confirmed 
histologically in all patients, and clinical and survival data were listed for use in this study (Table 3.1). 
The research protocol followed the tenets of the Declaration of Helsinki (World Medical Association 
Declaration of Helsinki 1964; ethical principles for medical research involving human subjects).
Table 3.1. Primers used in PCR
RASSF1a Forward Primer: 3’-GAAGGAGGGAAGGAAGGGTAAGG-5’
RASSF1a Reverse Primer: 5’-GGAGTTTGAGTTTATTGAGTTGCGG-3’
     
     
DNA Extraction and Sodium Bisulfite Modification
With the use of a column-based extraction kit (Qiagen Genomic tip 100/G; Qiagen Benelux BV, Venlo, The 
Netherlands), DNA was extracted from cell lines, frozen tumor material, and cultured uveal melanocytes 
according to the kit manufacturer’s guidelines. Genomic DNA was modified with sodium bisulfite (EZ 
Methylation Gold Kit; Zymo Research Corporation, Orange, CA.). Enzymatically methylated human DNA 
(Chemicon Europe Ltd., Hampshire, UK) was used as a positive control in all experiments.
Methylation Analysis
Methylation status of the promoter region was determined by polymerase chain reaction with specific 
primers and by melting temperature analysis and was further validated with restriction digestion 
analysis. Primers were designed using bisulfite-converted DNA sequences (Beacon Designer Software 
version 5.0; Premier Biosoft International, Palo Alto, CA) and amplified a region of the RASSF1a gene 
promoter CpG island (NCBI accession *605082; bases 353–618). Primers are shown in Table 3.2. PCR 
was carried out in a final volume of 21 µL containing 10 µL mix (iQ SYBR Green Supermix; Bio-Rad 
Laboratories BV, Veenendaal, The Netherlands), 1 µL (10 pmol/µL) of each primer, 8 µL H2O, and 1 µL 
bisulfite-converted DNA. PCR was initiated by hot start, followed by 40 cycles at 96°C for 15 seconds, 
60°C for 30 seconds, and 72°C for 30 seconds, and with a final melting curve from 70°C to 97°C with an 
increase in temperature of 0.2°C every 10 seconds. The fluorescence of SYBR Green was measured once 
per cycle to monitor template amplification.




Table 3.2. Clinical and Survival Data
Tumor ID Cell-type Survival in months Present status
Hypermethylated 
RASSF1a 
 UM 1 Spindle  198 Alive Present  
 UM 2 Mixed    29 Dead, metastases Present  
 UM 3 Mixed    95 Dead, metastases Present  
 UM 4 Spindle  31 Dead, metastases Present  
 UM 5 Spindle  50 Dead, metastases Present  
 UM 6 Epithelioid 57 Dead, unknown Not present  
 UM 7 Mixed    63 Dead, unknown Not present  
 UM 8 Spindle  179 Alive Not present  
 UM 9 Mixed    131 Alive Not present  
 UM 10 Mixed    124 Alive Not present  
 UM 11 Epithelioid 50 Dead, other cause Not present  
 UM 12 Mixed    13 Dead, metastases Present  
 UM 13 Epithelioid 128 Alive Present  
 UM 14 Epithelioid 30 Dead, metastases Not present  
 UM 15 Epithelio 21 Dead, unknown Failed  
 UM 16 Mixed    42 Dead, metastases Present  
 UM 17 Mixed    23 Dead, metastases Present  
 UM 18 Epithelioid 115 Dead, unknown Present  
 UM 19 Epithelioid 33 Dead, metastases Present  
 UM 20 Spindle  12 Dead, metastases Present  
 UM 21 Spindle  15 Dead, metastases Not present  
 UM 22 Mixed    187 Alive Present  
 UM 23 Epithelioid 167 Dead, metastases Present  
 UM 24 Spindle  2 Lost to follow up Not present  
 UM 25 Spindle  145 Alive Not present  
 UM 26 Mixed    131 Alive Present  
 UM 27 Mixed    13 Dead, other cause Not present  
 UM 28 Mixed    29 Dead, other cause Not present  
 UM 29 Spindle  122 Alive Not present  
 UM 30 Mixed    23 Dead, unknown Not present  
 UM 31 Epithelioid 33 Dead, metastases Present  
 UM 32 Spindle  24 Dead, metastases Not present  
 UM 33 Epithelioid 30 Dead, metastases Not present  
 UM 34 Mixed    13 Dead, metastases Present  
 UM 35 Spindle  101 Alive Present  
 UM 36 Mixed    34 Dead, metastases Present  
 UM 37 Epithelioid 36 Dead, unknown Not present  
 UM 38 Mixed    24 Dead, unknown Not present  




PCR amplification of bisulfite-treated DNA and subsequent melting analysis (iQ5 Real-time PCR 
Detection System; Bio-Rad Laboratories BV) allowed detection of heterogeneous methylation (in which 
the content and distribution of methylated cytosines differed between different molecules in the same 
sample). DNA melting peaks were acquired by measuring the fluorescence of SYBR Green during a linear 
temperature transition from 70°C to 97°C at 0.2°C each 10 seconds with accompanying software (Bio-
Rad Laboratories BV).
Restriction Digestion Analysis and Sequence Analysis
After amplification with specific primers for methylated DNA, the PCR-amplified fragments were 
digested using 4 U restriction enzymeRSA1 (Fermentas GmbH, St. Leon Rot, Germany) directly added to 
the PCR mixture (under conditions specified by the manufacturer). The RASSF1a amplicon of methylated 
DNA contains one RSA1 recognition site and is dependent on CT conversion and methylation of a CpG. 
The recognition site 5’-GT_AC-3 only appears when the first C in the GCAC sequence is converted to 
thymine, whereas the second must be methylated and remains C. Amplified products were analyzed by 
electrophoresis on a 2% agarose gel. DNA bands were excised from the gel, purified with a gel extraction 
kit (Nucleospin Extract II; Macherey-Nagel GmbH & Co., Düren, Germany), and sequenced on a DNA 
sequencing system (ABI PRISM 3700; Applied Biosystems, Foster City,CA).
Statistical Analysis
Survival analysis for RASSF1a promoter methylation was performed with Kaplan-Meier analysis and log 
rank test (SPSS version 12.0.1 for Windows; SPSS Inc., Chicago, IL). For comparison between the presence 
or absence of RASSf1a methylation and metastatic disease, the X2 test was performed.
Results
Methylation Analysis in Cell Lines, Primary Tumor Tissue, and Metastasis
To evaluate whether RASSF1a methylation may play a role in uveal melanoma, we analyzed the 
methylation status of the RASSF1a promoter region in a panel of uveal melanoma cell lines and archival 
fresh frozen tumor tissue using melting temperature analysis, sequencing, and restriction enzyme 
analysis.  In unmethylated DNA, all cytosines in a CpG dinucleotide are converted to thymines, but in 
methylated DNA such cytosines remain unchanged. Replacement of cytosines by thymines results in 
change of a CG base pair to a TA base pair in double-stranded DNA. Subsequently, the temperature at 
which DNA becomes single stranded is higher in methylated DNA. PCR performed on sodium bisulfite– 
converted DNA isolated from uveal melanoma cell lines showed a melting peak at 83.6° to 84.6°C in 10 of 
11 cell lines (all except Mel-290), which coincided with the peak of the positive control (full methylation). 
In cell line Mel-290, a melting peak was observed at 81.2° to 81.4°C, similar to the normal cultured 
melanocytes, indicating an unmethylated promoter (Figure 3.1). This result is consistent with the fact 




that the amplified RASSF1a amplicon contained 20 CpGs (primer design software predicts a melting 
temperature difference of 3.4°C).
Figure 3.1. Different melting peaks for the RASSF1a amplicon. Bisulfite treated DNA was amplified from cell lines, 
primary tumors, a metastatic lesion, and completely methylated DNA. Different melting peaks are shown that are 
also representative of corresponding samples. Melting peaks were obtained by plotting the negative derivative of 
fluorescence over temperature versus temperature(–d(RFU)/dT vs. T).
In addition, 39 primary tumors and a metastatic lesion in patient 31 were analyzed in the same manner 
as the cell lines. One tumor sample failed repeatedly in the PCR and was excluded (sample 15). Of the 
remaining 38 primary tumor samples, 19 (50%) included a methylated RASSF1a promoter region. Nine of 
these samples and the metastatic lesion showed an additional melting peak at 81.2° to 81.4°C, indicating 
the presence of methylated and unmethylated DNA in the same sample and signaling the presence of 
heterogeneous cell populations (Figure 3.1).
Restriction Digestion Analysis and Sequence Analysis
Amplified PCR fragments were digested using the restriction enzyme RSA1. Incubation with RSA1 and gel 
analysis of the fragments confirmed the methylation status as already observed with the melting curve 
analysis. Ten of 11 cell lines showed bands representative for methylated DN; again, hypermethylation 
was not observed in the melanocyte culture Mel-1a (normal control; Figure 3.2). Of the 38 primary uveal 
melanomas, 19 samples were found to be methylated by restriction enzyme analysis. These were in 
exact correspondence with those found to be methylated in melting curve analysis. As a final check, 
methylation of RASSF1a was confirmed by direct sequencing of the RASSF1a product in all samples 
(Figure 3.3 depicts an example of cell lines Mel-270 and Mel-290).
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Figure 3.2. Restriction digestion analysis. Agarose gel electrophoresis showing RASSF1a-amplified DNA fragments of 
all uveal melanoma cell lines after digestion with restriction enzyme RsaI. The amplicon contains one RsaI recognition 
site and is dependent on CT conversion and CpG methylation. The recognition site GT_AC only appears when the 
first C in the GCAC sequence is converted to thymidine; the second must be methylated and remains a C. In vitro–
methylated DNA was used as a positive control, and a normal uveal melanocyte culture was used as a normal control. 
With the exception of cell line Mel-290, all cell lines showed complete methylation of the RASSF1a promoter region.
Figure 3.3. Sequence analysis of cell lines Mel270 and Mel-290. Sequence results from uveal melanoma cell line Mel-
270 DNA (top) and cell line Mel-290 (bottom). The absence of cytosines in amplified bisulfite-converted DNA of cell 
line Mel-290 confirmed the presence of an unmethylated RASSF1a promoter region in this cell line, as found earlier 
by digestion analysis.
Survival Analysis
To assess whether the presence of hypermethylated RASSF1a was correlated with a clinical parameter, 
correlations between methylation status and melanoma-associated survival and development of 
metastatic disease were evaluated. Of the initial group of 39 patients, one was lost after 2 months of follow-




up. Mean survival of the remaining 38 patients was 68 months (range, 12–198 months). Development 
of metastatic disease correlated with the presence of a hypermethylated RASSF1a promoter region (P 
= 0.041). An association between disease free survival and the presence of a hypermethylated RASSF1a 
promoter could not be established, though a positive trend was observed (P = 0.063; log rank test), as 
shown in Figure 3.4.
Figure 3.4. Kaplan-Meier analysis and log rank test showed the difference in disease-free survival according the 
absence or presence of a hypermethylated RASSF1a promoter region in primary uveal melanoma tumor tissue 
(P = 0.063); log rank test). Although not significant, a positive trend was observed.
Discussion
Epigenetic modification of gene expression is important in tumor development (Das and Singal, 2004, 
Baylin and Ohm, 2006). Methylation of TSG is now commonly analyzed in tumors and even rivals mutation 
and deletion as the main mechanism in tumor development in certain tumors Robertson, 2005). RASSF1a 
is an example of a potential TSG that has been studied in many tumors in which methylation correlates 
with reduced expression (Pfeifer and Dammann, 2005). 
The frequent methylation of the RASSF1a gene in uveal melanoma cell lines (91%) and also in primary 
tumor tissue (50%) suggests that RASSF1a also plays a role in uveal mela-noma pathogenesis. It has been 
suggested that the RASSF1a protein acts at the level of G1/S-phase cell cycle progression (Shivakumar 
et al., 2002). Loss of expression of RASSF1a as caused by hypermethylation could therefore reduce G1/S-
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phase cell cycle control. In lung and breast tumor–derived epithelial cells, reintroduction of RASSF1a 
expression resulted in growth arrest that was correlated with reduced cyclin D1 protein accumulation, 
whereas iRNA-mediated inhibition of RASSF1a expression resulted in abnormal accumulation of native 
cyclin D1 (Shivakumar et al., 2002). Shivakumar et al. reported that RASSF1A functions as a negative 
regulator of cell proliferation through the inhibition of G1/S-phase progression. 
Loss of one copy of chromosome 3 (monosomy 3) has been reported in approximately 50% of all uveal 
melanomas and is associated with metastatic behavior of this type of tumor. Until now, no specific TSG 
at chromosome 3 has been identified that is targeted by this deletion. Therefore, the location of the 
RASSf1a gene on chromosome 3p21.3 could be of utmost importance for uveal melanoma. Although 
methylation of RASSF1a may not be held wholly responsible for uveal melanoma development, it could 
be a contributing factor for uveal melanoma tumor formation and progression. RASSF1a methylation 
could be the second hit in a classic TSG inactivation in uveal melanoma with monosomy 3. Loss of 
one RASSF1a copy because of monosomy 3, in combination with hypermethylation of the other copy, 
could promote progression through the G1/S phase of the cell cycle, stimulating the formation of uveal 
melanoma tumor.
The high frequency of RASSF1A methylation in uveal melanoma cell lines compared with primary tumors 
has also been observed in cell lines derived from breast and ovarian cancer (Agathanggelou et al., 2001). 
In addition, the methylation of p16INK4a in uveal melanoma was shown to be more common in uveal 
melanoma cell lines, in contrast to primary tumors (Van der Velden et al, 2001). This observation might 
indicate that tumors with RASSF1A methylation are more oncogenic and are likely to be established as 
cell lines and is consistent with the observation that, in contrast to the cell lines, one third of the positive 
tumors presented methylated and unmethylated DNA, suggesting that heterogeneity of the primary 
tumor is lost in the cell line cultures. 
An obvious example of tumor heterogeneity is shown in Figure 3.1. Primary tumor sample 11 seems 
to be unmethylated, but the tiny shoulder at the position of methylated DNA suggests the presence 
of a minimal amount of methylated DNA. An attempt to validate this minor methylated DNA fraction 
through digestion analysis was inconclusive. Future analysis using more sensitive and advanced 
techniques should be conducted to clarify the possible presence of small quantities of methylated DNA 
in such samples. 
Although RASSF1a methylation alone may not be responsible for uveal development, it could be a 
contributing factor for uveal melanoma tumor formation and progression. The three cell lines derived 
from one patient (OMM-1.3 and OMM-1.5 are from two different metastases, and Mel-270 is from the 
primary tumor) were all methylated. The metastatic lesion derived from the same patient bearing the 
RASSF1a methylated tumor 31 showed two melting peaks, indicating a mixture of methylated and 
unmethylated DNA probably as a result of contamination of the sample with normal tissue. Furthermore, 
RASSF1a promoter hypermethylation was found to be associated with the development of metastatic 
disease (P = 0.041), and the presence of methylation in the primary tumor and its metastasis indicates 
a role for methylated RASSF1a in tumor progression. A correlation with decreased survival could not be 




established in this study, but a positive trend was observed (P = 0.063). 
Based on these findings, we propose that the epigenetic regulation of the RASSF1a gene through 
promoter hypermethylation may play an important role in the development and progression of uveal 
melanoma, which once again adds to the proposed high frequency of methylation in uveal melanoma 
compared with normal tissue. We also propose that RASSF1a might serve as a tumor marker in uveal 
melanoma.
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PURPOSE. Recently, a segregation study in families with uveal and cutaneous melanoma identified 
9q21 as a potential locus harboring a tumor-suppressor gene (TSG). One of the genes in this area, RASEF, 
was then analyzed as a candidate TSG, but lack of point mutations and copy number changes could not 
confirm this. In this study, the RASEF gene was investigated for potential mutations and gene silencing 
by promoter methylation in uveal melanoma.
METHODS. Eleven uveal melanoma cell lines and 35 primary uveal melanoma samples were screened 
for mutations in the RASEF gene by high-resolution melting-curve and digestion analysis. Expression 
of RASEF was determined by real-time RT-PCR in all cell lines and 16 primary uveal melanoma samples, 
and the methylation status of the promoter of the RASEF gene was analyzed and confirmed by direct 
sequencing.
RESULTS. Mutation screening revealed a known polymorphism (R262C; C—›T) in exon 5 of the RASEF 
gene that displayed a normal frequency (54%). Of the primary uveal melanomas, 46% presented a 
heterozygous genotype, and 10 (91%) of 11 cell lines showed a homozygous genotype. Melting-curve 
analysis indicated loss of heterozygosity in at least two primary tumors. Low RASEF expression in the cell 
lines and primary tumors correlated with methylation of the RASEF promoter region. Homozygosity and 
methylation of the RASEF gene in primary tumors were associated with decreased survival (P = 0.019).
CONCLUSIONS. Homozygosity, in combination with methylation, appears to be the mechanism 
targeting RASEF in uveal melanoma, and allelic imbalance at this locus supports a TSG role for RASEF.





Uveal melanoma is the most common primary intraocular neoplasm in adults, with an annual incidence 
of six to eight per million in Caucasian populations (Egan et al., 1988). In contrast to cutaneous 
melanoma, clustering of uveal melanoma in families is extremely rare (Van Hees et al., 1998; Kodjikian et 
al., 2003; Smith et al., 2007). Occurrence of both uveal melanoma and cutaneous melanoma in a single 
family has been observed (van Hees et al., 1998). Recently, Jönsson et al. (Jönsson et al., 2005) revealed a 
genetic component in three such families, in which members are affected by either uveal or cutaneous 
melanoma. Linkage analysis in these families identified a potential uveal melanoma susceptibility locus 
on chromosome 9, area q21. This locus has a long history in melanoma that started with detection of 
isochromosome 9q with cytogenetic analysis (Kopf et al., 1992; Albino et al., 1992). Loss of heterozygosity 
(LOH) of markers at 9q22 was subsequently frequently reported and was shown to be associated with 
proliferation and tumor progression (Boni et al, 1998; Kumar et al., 1999).
Recently, single nucleotide polymorphism (SNP) analysis has confirmed the LOH of this locus in 
melanoma, while genome-wide analysis in dizygotic twins for nevi numbers also showed linkage with 
this 9q region (Zhu et al., 2007; Stark et al., 2007). In addition, a gene slightly distal to RASEF, RMI1, has 
recently been shown to be a risk factor for cutaneous melanoma, whereas the locus for familial melanoma 
susceptibility is located on the short arm of chromosome 9 (Cannon-Albright et al., 1992; Boni et al., 1998; 
Broberg et al., 2007). Cutaneous melanomas are often characterized by loss of the cell-cycle regulator 
p16 and/or activation of the RAS-RAF-ERK pathway (Cohen et al., 2002; Satyamoorthy et al., 2003). These 
hallmarks of melanoma are also recognized in uveal melanoma, although the underlying mechanisms 
differ (Weber et al., 2003; Calipel et al., 2006). Whereas in cutaneous melanoma, p16 is commonly lost 
by chromosomal deletion of the CDKN2A gene, the preferential mechanism in uveal melanoma appears 
to be silencing of the p16-encoding CDKN2A promoter by methylation (van der Velden et al., 2001). 
Mutations in BRAF, NRAS, or c-kit lead to constitutive ERK activation in most cutaneous melanomas (van 
Elsas et al., 1996; Davies et al., 2002). However, mutations in BRAF have only rarely been reported in uveal 
melanoma, whereas activating NRAS and c-kit mutations have never been reported (Zuidervaart et al., 
2005). Still, ERK activation is also present in uveal melanoma, and this knowledge leads to the question 
of what causes ERK activation in the absence of activating mutations in BRAF, NRAS, or c-kit (Weber et al., 
2003; Zuidervaart et al., 2005; Calipel et al., 2006).
The RASEF (RAS and EF hand domain containing) gene is located on chromosome 9, area q21, and encodes 
a protein with calcium-binding EF-hand and Ras GTPase (Rab family) motifs (http://www.genome.ucsc.
edu/ provided in the public domain by the Genome Bioinformatics Group, University of Santa Cruz, CA); 
it is also known as RAB45 or FLJ31614.22 (Sweetser et al., 2005). Based on the functional domains in RASEF, 
the gene product may be engaged in the RAS pathway and in combination with evidence for linkage 
of the RASEF region with cutaneous and uveal melanoma, molecular analysis of this gene is warranted. 
In line with the analysis of cutaneous melanoma reported by Jönsson et al., (Jönsson et al., 2005) we 




Cell Lines and Primary Uveal Melanoma Specimens
In total, 11 cell lines derived from primary uveal melanomas (92.1; OCM-1, -3, and -8; and Mel-202, -270, 
-285, and -290) and uveal melanoma metastases (OMM-1, -2.3, and -2.5) were analyzed. All melanoma 
cell lines were cultured in RPMI 1640 medium (Invitrogen-Gibco, Paisley, Scotland, UK) supplemented 
with 3 mM L-glutamine (Invitrogen- Gibco), 2% penicillin streptomycin, and 10% FBS (Hyclone, Logan, 
UT). All cell cultures were incubated at 37°C in a humidified 5% CO2 atmosphere. Archival frozen tumor 
specimens of primary uveal melanoma came from 35 patients who attended the Leiden University 
Medical Center between 1988 and 1996. All tumors were primary lesions with a tumor diameter greater 
than 12 mm, a prominence greater than 6 mm, and no treatment before enucleation. The validity of 
the diagnosis of uveal melanoma was confirmed histologically in all cases, and clinical and survival data 
were listed for use in the study (Table 4.1). The research protocol followed the tenets of the current 
version of the Declaration of Helsinki (World Medical Association Declaration of Helsinki 1964; Ethical 
Principles for Medical Research Involving Human Subjects).
Table 4.1. Tumor Characteristics and Survival Data of 35 Uveal Melanoma Patients Sorted by Methylation Status and 
RASEF Genotype







UM1 Spindle 210 Alive Not present Hom C
UM2 Mixed 29 Dead, due to metastases Not present Het
UM3 Mixed 95 Dead, due to metastases Not present Hom C
UM4 Spindle 31 Dead, due to metastases Not present Hom T
UM5 Spindle 50 Dead, due to metastases Present Hom T
UM6 Epithelioid 57 Dead, due to metastases Not present Hom T
UM7 Mixed 63 Dead, other cause Not present Het
UM8 Spindle 191 Alive Not present Het
UM9 Mixed 131 Alive Not present Het
UM10 Mixed 136 Alive Not present Het
UM11 Mixed 13 Dead, due to metastases Present Hom T
UM12 Epithelioid 137 Dead, due to metastases Not present Hom T
UM13 Epithelioid 30 Dead, due to metastases Present Het*
UM14 Mixed 42 Dead, due to metastases Not present Het
UM15 Mixed 23 Dead, due to metastases Present Het
UM16 Epithelioid 115 Alive Not present Hom C
UM17 Epithelioid 33 Dead, due to metastases Present Het
UM18 Spindle 12 Dead, due to metastases Present Hom T
UM19 Spindle 15 Dead, due to metastases Not present Hom T












UM20 Mixed 187 Alive Not present Het
UM21 Epithelioid 167 Dead, due to metastases Present Het*
UM22 Spindle 2 Lost to follow up Not present Het
UM23 Spindle 152 Dead, unknown cause Not present Het
UM24 Mixed 143 Alive Not present Het
UM25 Mixed 29 Dead, other cause Not present Het
UM26 Spindle 122 Alive Not present Hom T
UM27 Mixed 23 Dead, due to metastases Present Hom C
UM28 Epithelioid 33 Dead, due to metastases Present Hom C
UM29 Spindle 24 Dead, due to metastases Not present Hom C
UM30 Spindle 113 Alive Present Hom C
UM31 Mixed 34 Dead, due to metastases Not present Hom T
UM32 Epithelioid 63 Dead, due to metastases Not present Hom T
UM33 Mixed 24 Dead, due to metastases Not present Hom C
UM34 Mixed 106 Alive Not present Het
UM35 Mixed 94 Alive Present Hom T
* Loss of heterozygosity  / Allelic imbalance
DNA and RNA Extraction and Sodium-Bisulfite Modification
Using a column-based extraction kit (Genomic tip 100/G; Qiagen Benelux BV, Venlo, The Netherlands), 
DNA was extracted from the cell lines and frozen tumor material, according to the manufacturer’s 
guidelines. RNA was also extracted with a column-based extraction kit (RNeasy mini kit; Qiagen 
Benelux) from tumors in which enough frozen material was available (n=16). RNA was converted to 
cDNA (iScript cDNA synthesis kit; Bio-Rad Laboratories BV, Veenendaal, the Netherlands), according to 
the manufacturer’s guidelines. Genomic DNA was modified with sodium bisulfite (EZ Methylation Gold 
kit; Zymo Research Corp., Orange, CA). Enzymatically methylated human DNA (Chemicon Europe Ltd., 
Hampshire, UK) was used as the positive control in all experiments. DNA and RNA concentrations were 
determined by spectrophotometer (model ND-1000; NanoDrop Technologies Inc., Wilmington, DE).
Mutation Screening and Genotyping
A 96-well light scanner (Idaho Technologies Inc., Salt Lake City, UT) for high-resolution melting-curve 
analysis was used to scan all amplicons of the RASEF gene. The primers are shown in Table 4.2. DNA 
samples were amplified with a double-stranded DNA-binding dye (LC Green Plus; Idaho Technologies). 
Melting curves were analyzed in plots showing differences in fluorescence. The shift and curve shapes 
of melting profiles were used to distinguish between samples from control subjects and patients. PCR 
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reaction with the green dye contained PCR buffer (Invitrogen, Breda, The Netherlands), 1.5 mM MgCl
2
, 
40 μM dNTPs, 1:10 diluted green dye, 0.4 mM of forward and reverse primers, and 1 unit Taq polymerase 
per 10-μL reaction (Fast Start; Roche Diagnostics BV, Almere, The Netherlands). PCR consisted of an 
initial denaturation at 94°C for 6 minutes followed by 40 cycles consisting of 15 seconds at 96°C, 30 
seconds at 58°C, and 60 seconds at 72°C, and the PCR ended with a 1-minute denaturation at 94°C. After 
amplification, the amplified fragments (exon 5) were digested using 4 units of the restriction enzyme 
BstU1 (New England Biolabs, Beverly, MA) directly added to the PCR mixture. Analysis was performed by 
overnight digestion of the amplified fragments at 60°C. The BstU1 enzyme recognizes and cleaves the 
5’-CG^CG-3’ sequence. PCR products were separated on a 2% agarose gel in 1x TBE (0.09 M Tris-borate, 
0.002 M EDTA; pH 8.2).
RASEF Expression
The expression of RASEF in 16 tumors for which RNA was available was analyzed with real-time RT-PCR and 
specific primers, which are shown in Table 4.2. PCR was performed as described earlier (Maat et al., 2007).
Table 4.2. RASEF Primers Used for Mutation Detection, Expression Analysis, and Methylation Analysis
Primer Sequence
Exon 1 Forward 3’-GGCAAGCAGCGGTGGACTC-5’
Reverse 5’-GTAGGTGAAGGAAGACAAGCAACTC-3’
Exon 2 Forward 3’-TCTTCCCTTCCTTCCGTTCATTCTG-5’
Reverse 5’-GTCCACCTATATCATAGTGTGACAATGC-3’
Exon 3 Forward 3’-TTCTCTTCATCTGTAATATATAGGGCTTAACG-5’
Reverse 5’-CCCTCTCCGTAGAAACCACCTC-3’
Exon 4 Forward 3’-TCACCTTCCCTGTGTAGGAGAAC-5’
Reverse 5’-CTGAGATGCTGAGGCTGTTCC-3’
Exon 5 Forward 3’-CAAAGCAATTCAAAGTGAGTTTGTAAGC-5’
Reverse 5’-TGAGGATGTGGTCTAACAGGAAGTG-3’
Exon 6 Forward 3’-GTGTGGGAGGGTGACAGGAC-5’
Reverse 5’-AAATCATTAGAAAGTAAAGAAGATATTAGCAAAG-3’
Exon 7 Forward 3’-AAAGGGTCTGGGAGGGTAGG-5’
Reverse 5’-AAACAAGTGAAATGTAAATGTAATGAGC-3’
Exon 8 Forward 3’-CCCAATGATACTTTCCTTGTCTCTCTTTC-5’
Reverse 5’-ACTTACTTGAGGCTCTCCTTTAAGAAATTAC-3’
Exon 9 Forward 3’-TAGTTACATTAGAAGTTTGAGTAGTGTGC-5’
Reverse 5’-TTAACATACCTGTCATAGCCTAGAGG-3’
Exon 10 Forward 3’-AGCCCTCAGGTAAATTGGTCTTCC-5’
Reverse 5’-TGACAGATAGAAGGCAAATAAGGTGAC,-3’






Exon 11 - 12 Forward 3’-TGACATAAGGGATGAAGAGACATTTGG-5’
Reverse 5’-TTATCAACCGAAATACGAGCCATACC-3’
Exon 13 Forward 3’-CAATGGAATTATTTACATCGTGCTCTC-5’
Reverse 5’-TTTGAGTATGAAGAACATCAAGTGG-3’
Exon 14 Forward 3’-GGCAACACAAACTGACTGATGATG-5’
Reverse 5’-TTTCTGTTTCTCCATTATGATTTCTTACCTC-3’
Exon 15 Forward 3’-TGTTGCTGTTGTTCTGTGGTCATC-5’
Reverse 5’-ACCGACTTCAAAGCCATTAAACCC-3’
Exon 16 Forward 3’-AAGGGCTTCATTTAATTGTGTGTATTTC-5’
Reverse 5’-CCACCATGACTGACAGATAAGAGAG-3’
Exon 17 Forward 3’-TATGAAGATTAAGTCAAGACCTATAAAGC-5’
Reverse 5’-GACTTTGTGGGTAACCTAATTCAGC-3’
RASEF QPCR Forward 3’-ATCAGACTTCAAAGCACAGAAATGG-5’
Reverse 5’-TTCCTCTTCCAACTCACTCAACTG-3’
RASEF Bisulfite Forward 3’-GGGATGGAGGCGGATGGG-5’
Reverse 5’-CCGCAACTCCGTACACAATACC-3’
RASEF PAP Forward 3’-GGACGGAGAGGAGTTGGTTCGGTTG-ddC-5’
Reverse 5’-CCGCAACTCCGTACACAATACCCGAAA-ddC-3’
Methylation Analysis
We applied bisulfite modification of tumor DNA in combination with PCR, as this introduces sequence 
differences between methylated and unmethylated DNA that can be analyzed with several methods. 
The sequence differences were initially determined with melting-temperature analysis, as this method 
provides both quantitative and qualitative measures of methylation (Figure 4.3). The methylation status 
of the RASEF promoter region was determined by polymerase chain reaction with specific primers and 
by melting-temperature analysis and was further validated with a restriction digestion analysis. Primers 
were designed on computer (Beacon Designer Software ver. 5.0; Premier Biosoft International, Palo Alto, 
CA) using bisulfite converted DNA sequences and amplified a CpG island in the RASEF gene promoter 
(Consensus CDS [Coding Sequence] accession number 6662.1; Gene ID 158158/ http://www.ncbi.nlm.nih.
gov/ a genome database hosted by the National Center for Biotechnology Information, Bethesda, MD). 
The primers are shown in Table 4.2. PCR was performed exactly as described earlier (Maat et al., 2007).
Melting-Temperature Analysis
A melting-temperature analysis was performed as described earlier (Maat et al., 2007)
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Restriction Digestion Analysis and Sequence Analysis
After amplification with specific primers for bisulfite-converted DNA, the PCR-amplified fragments were 
digested with 4 units of restriction enzyme HinfI (Fermentas GmbH, St. Leon Rot, Germany) directly added 
to the PCR mixture (under conditions specified by the manufacturer). The HinfI enzyme recognizes and 
cleaves the 5’-G^ANTC-3’ sequence. This sequence is not present in unmodified DNA and in modified 
unmethylated DNA. The RASEF amplicon of methylated DNA contains one HinfI recognition site and 
is dependent on both CT conversion and methylation of a CpG. The recognition site 5’- G^ANTC-3’ 
appears only when the first C in the 5’-GANCC-3’ sequence is converted into thymine, whereas the 
second must be methylated and remains a cytosine. PCR products were separated on a 2% agarose gel 
in 1x TBE (0.09 M Tris-borate, 0.002 M EDTA; pH 8.2). DNA bands were excised from the gel, purified using 
a gel extraction kit (Nucleospin Extract II; Macherey-Nagel, GmbH, Düren, Germany) and sequenced 
(Prism 3700 DNA sequencing system; Applied Biosystems, Foster City, CA).
Pyrophosphorolysis-Activated Polymerization
In the pyrophosphorolysis-activated polymerization (PAP) reaction, primers are used that contain a 
dideoxy-nucleotide (ddNTP) at their 3’ terminus and hence will not be extended. A polymerase with 
Pyrophosphorolysis activity can remove the dideoxy-cytosine and thereby activate polymerization. 
Since this pyrophosphorolysis activity is dependent on double-stranded DNA, only primers that 
perfectly match the template will be activated. The specificity of Pyrophosphorolysis allows us to amplify 
specifically the minute amounts of methylated RASEF DNA in the background of unmethylated DNA. 
The PAP products can be further validated with sequence analysis for internal CpGs. The primers are 
shown in Table 4.2. The amplification was performed in a final volume of 25 mL containing 5 mL 5x PAP 
buffer (prepared as described by Liu and Sommer), 0.3 mL (10 picomoles/mL) of each primer, 0.5 mL 
Taq polymerase (KlenTaq; DNA Polymerase Technology, Inc., St. Louis, MO), 17.9 mL H2O, and 1 mL DNA 
sample (Liu and Sommer, 2004). Amplification was initiated by hot start, followed by 40 cycles at 94°C for 
15 seconds, 60°C for 40 seconds, 64°C for 40 seconds (T-anneal); 68°C for 40 seconds (pyrophosphorolysis 
activity); and 72°C for 40 seconds (elongation), and using a final melting curve from 70°C to 97°C with an 
increase in temperature of 0.2°C every 10 seconds. PCR products were separated on a 2% agarose gel in 
1x TBE (0.09 M Tris-borate, 0.002 M EDTA; pH 8.2).
Statistical Analysis
Survival analysis for RASEF promoter methylation was performed using a Kaplan Meier analysis and log 
rank test (SPSS ver. 14.0 for Windows; SPSS Inc., Chicago, IL). For a comparison between the presence and 
absence of RASEF methylation and metastatic disease and tumor characteristics, the X2 test and analysis 
of variance were performed.





Mutation Screening in Uveal Melanoma
To analyze RASEF as a tumor-suppressor gene (TSG) candidate, we first investigated the gene for 
mutations. Mutation screening was performed in two steps: first, the 17 exons were prescreened by 
high-resolution melting-curve analysis. Though melting-curve analysis showed few variations, we 
nevertheless generated sequences for 2 tumor samples of each exon both sequenced with the forward 
and the backward PCR primer. We detected a sequence variation, which was a known polymorphism 
in exon 5 of RASEF encoding a R262C (C—›  T; Arginine —› Cysteine) substitution (Figure 4.1). This SNP 
occurs frequently in the population, with reported frequencies between 50% and 58% of the Caucasian 
population (Sweetser et al., 2005). In 10 of the 11 cell lines, a homozygous genotype of the T allele was 
observed. The primary uveal melanomas (n = 35) displayed a normal frequency of the SNP (54%), with 
16 uveal melanomas presenting a heterozygous genotype (Table 4.1). However, both melting curve 
analysis and restriction enzyme analysis revealed imbalance of the alleles in two samples. Whereas in 
gel analysis of BstUI digested RASEF, exon 5 PCR indicated the presence of the C-allele, melting-curve 
analysis indicated that the relative concentration of the C-allele was at least 10-fold lower than the 
T-allele in UM13 and -21 (Figure 4.1).
Figure 4.1. (A) Melting-curve analysis of the RASEF R262C polymorphism in control and primary uveal melanoma and 
cell lines. Red: heterozygous control and tumor samples; blue: heterozygous primary uveal melanoma samples with 
a lowered difference plot that is not seen in control samples. (B) A calibration curve was created with dilutions of the 
T allele in a constant background of the C allele. Based on this curve it was estimated that the relative abundance 
of the alleles in the primary uveal melanoma samples 13 and 21 was decreased at least 10-fold. (C–E) RASEF exon 5 
sequence analysis of primary uveal melanomas shows the R262C polymorphism at position 37. The cytosine from the 




The allelic imbalance observed in the primary uveal melanoma was followed up by RASEF RT-PCR 
expression analysis. In the cell lines, two groups were distinguishable, based on expression levels. In 6 
of 11 uveal melanoma cell lines (92.1; Mel 202 and -270; and OMM-1, -2.3, and -2.5) an approximately 
30- to 100-fold reduced expression of RASEF was displayed compared with the other cell lines (OCM1, -3, 
and -8; Mel285 and -290; Figure 4.2). Cell lines Mel270 and OMM-2.3 and -2.5 are derived from the same 
patient and fell into the same group. Among the uveal melanomas cell lines with low RASEF expression, 
a homozygous (TT) genotype prevailed. When primary tumors were analyzed, variable levels of RASEF 
expression were also observed, but clustering into two groups was not as marked, and the absolute 
expression levels differed even more. One sample failed in the expression analysis (UM15). Correlating 
the expression levels with the genotypes of the tumors revealed that the homozygous tumors tended to 
present a lower RASEF expression (P = 0.015), as was the case in one tested uveal melanoma presenting 
allelic imbalance (UM13).
Figure 4.2. Expression analysis for RASEF in cell lines and primary uveal melanoma (UM), measured with real-time 
RT-PCR. Expression was normalized with the control gene RPS11. The change (x-fold) of expression is calculated 
compared with the median expression level. The RASEF genotypes of the samples are indicated in the graph. UM13 
displays loss of the C allele indicated by a lowercase c. UM15 failed in the expression analysis.
Methylation Analysis
Because we did not detect mutations that could explain the low RASEF expression in the primary 
uveal melanomas and the cell lines, we considered epigenetic regulation as the possible mechanism 
of downregulation. All five RASEF-expressing cell lines contained an unmethylated promoter while 
hypermethylation of all CpGs within the amplicon was present in all six cell lines that lacked RASEF 
expression. The analysis of methylation with melting temperature was confirmed by sequence analysis 
(Figure 4.3). In primary uveal melanomas, methylation was much more heterogeneous and never 




reached the level of methylation observed in the cell lines. Uveal melanoma samples 15 (failed in 
expression analysis) and 21 displayed the highest methylation but also contained an equimolar level of 
unmethylated RASEF. In the other uveal melanoma samples with methylated RASEF, a minor fraction of 
the CpGs was methylated. Still, there was a correlation between methylation and expression of RASEF in 
the primary tumor samples, although not as obvious as in the cell lines.
Figure 4.3. (A) Melting-temperature analysis of amplified RASEF product reveals the methylation of primary uveal 
melanoma samples and cell lines. Blue: methylated samples; green and purple: samples with a mixed methylation 
pattern; red: unmethylated samples. (B) Methylation in the promoter region of the RASEF gene in primary uveal 
melanoma sample 25, as shown by sequence analysis after PAP. After bisulfite treatment and PCR, unmethylated 
cytosines converted into thymidine. Methylated cytosines remained unchanged.
To validate methylation in primary tumors, we used restriction- enzyme analysis. By HinfI digestion, we 
were able to confirm RASEF methylation in primary uveal melanoma (data not shown). Next, we set out 
to isolate the methylated fraction and applied PAP. By applying PAP, we were able to show completely 
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methylated alleles and thereby validate melting temperature analysis in five tumors that had shown a 
methylated fraction in the background of unmethylated DNA. In one sample, a methylated allele was 
detected in a tumor that had shown a normal curve with melting-temperature analysis, suggesting a 
very low level of the methylated allele (Figure 4.3).
Survival
The mean follow-up of the 35 patients was 78 months (2–210 months), and 20 patients had died of 
tumor-related metastasis at the time of analysis. Two patients had died of a metastasis from another 
primary tumor (UM7 and UM25), one patient was lost to follow-up (UM22) after 2 months, and two 
patients had died of unknown causes. The presence of methylation within the RASEF promoter region 
correlated with death due to metastatic disease (P = 0.024; log rank test). The genotype of the 35 tumors 
did not correlate to cell type, methylation status, or the development of metastatic disease (P = 0.441; 
Pearson X2).
Although the genotype itself was not associated with metastatic death, patients with a homozygous 
genotype and methylation of the RASEF gene (n = 7) had a significantly higher risk of development of 
metastasis than did patients with a heterozygous genotype and no methylation (survival 51 +/- 15.5 vs. 
161 +/- 19.0 months; P = 0.019).
Figure 4.4. Kaplan-Meier analysis and log rank test showed the difference in survival according to genotype and 
presence or absence of methylation of the promoter region of the RASEF gene (P = 0.019).





Linkage analysis in uveal and cutaneous melanoma families identified the 9q21 region as a locus for 
a potential TSG involved in the development of melanoma. In addition, LOH analysis in two uveal 
melanomas from members of the families in which linkage was identified indicated 9q21 to be the 
possible region for a TSG (Jönsson et al., 2005). The 9q21 region harbors the RASEF gene, which is 
potentially involved in the RAS pathway prominent in the development of melanoma (Padua et al., 1984; 
Rimoldi et al., 2003). As patients with melanoma from the family just mentioned had been analyzed 
for RASEF mutations, we set out to analyze sporadic uveal melanoma and uveal melanoma cell lines. 
In line with the findings of Jönsson et al., (Jönsson et al., 2005) we did not detect any mutations in 
the RASEF gene other than a known SNP (Jönsson et al., 2005; Sweetser et al., 2005). Using this SNP, 
we detected allelic imbalance in some of the tumors that were heterozygous for this marker (UM13 
and -21). Because the imbalances were not complete, we suspect tumor heterogeneity in the primary 
tumors in contrast to the cell lines, all of which, with one exception, displayed a homozygous genotype. 
Gene expression analysis revealed that 5 of 11 uveal melanoma cell lines had high RASEF expression, 
whereas the others hardly showed expression. As almost all the low expression cell lines displayed 
the homozygous T-allele, there appears to be an association between expression and genotype. This 
apparent association, however, could also be based on the small number of cell lines that were tested 
and the fact that three cell lines were derived from the same patient (Mel 270, OMM 2.3, and OMM 2.5). 
In the primary tumors, expression varied widely and often exceeded the expression seen in the cell lines. 
Among the uveal melanomas with low RASEF expression a homozygous genotype prevailed, but this 
fact does not favor a specific allele. This finding may indicate that there is no risk factor linked to either 
allele and that the low expression is more likely due to a somatic alteration. As we had not observed 
any mutations in the cell lines, we subsequently considered epigenetic modifications as the cause of 
low RASEF expression. Indeed, all cell lines that did not express RASEF contained a methylated promoter, 
whereas all cell lines with expression lacked this methylation, confirming our hypothesis. Hereafter, we 
performed demethylation experiments with 5-azacytidine, which revealed a highly induced expression 
in a cell line with methylated RASEF. Demethylation of an unmethylated cell line resulted in the opposite 
effect. The demethylating agent is highly toxic and may explain downregulation of RASEF expression 
in the unmethylated cell line. Toxicity of 5-azacytidine and demethylation of all the other genes during 
treatment are the reasons that we reserve functional analysis using genetically modified cell lines for 
follow-up research. The primary uveal melanomas displayed heterogeneity for RASEF methylation but 
never reached levels above ~ 50% methylation, and most commonly only a part of the CpGs present 
in the promoter region was methylated. Furthermore, methylation not only coincided with low 
expression but also with a homozygous genotype, which suggests a combination of methylation and 
LOH being the mechanism of loss of expression. The additional effect of LOH seems to be associated 
with the aggressiveness of the tumor, because homozygous tumors with a methylated RASEF promoter 
region tended to have a decreased survival compared with heterozygous tumors without methylation 
(P = 0.019; Figure 4.4). To confirm the suggested mechanism, we compared the RASEF homozygous 
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genotype of four tumors with the genotype of their peripheral blood leukocytes, also obtained at 
time of enucleation. One person, in whom the tumor showed a nearly complete homozygous T allele 
genotype, revealed a heterozygous genotype in leukocyte DNA, confirming the mechanism of LOH in 
tumor tissue (Figure 4.5). Of interest, in the tumor tissue of this patient, the RASEF gene was methylated, 
furthermore confirming our conclusion.
Figure 4.5. Digestion analysis of DNA from a patient in whom the tumor (UM35, right) showed a nearly complete 
homozygous T-allele genotype revealed a heterozygous genotype in leukocyte DNA (left), confirming the mechanism 
of LOH in tumor tissue.
We conclude that homozygosity in combination with methylation is the mechanism that targets RASEF 
in uveal melanoma, appointing RASEF as a bona fide tumor suppressor that is epigenetically silenced in 
uveal melanoma. Allelic imbalance at this locus supports a tumor-suppressor role for RASEF; however, 
analysis of RASEF in proliferation, survival, and migration of uveal melanoma is needed to confirm this.
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PURPOSE. Mutations in the genes that control cell proliferation in cutaneous melanoma are generally 
uncommon in uveal melanoma. Despite the absence of known activating mutations, the RAF-MEK-ERK, 
or mitogen-activated protein kinase (MAPK), pathway is usually activated in uveal melanoma. An assay 
with increased potential to identify mutations is now available, and this study was therefore conducted 
to reanalyze uveal melanoma cell lines and primary tumors for this mutation.
METHODS. Eleven uveal melanoma cell lines and 45 primary uveal melanomas were analyzed for 
mutations in exon 15 of the B-RAF gene by using pyrophosphorolysis-activated polymerization (PAP). 
Mutations were validated by sequencing of the PAP product.
RESULTS. B-RAF mutations were detected in cell lines OCM-1 and -3 (V600E) and in six primary uveal 
melanomas. The V600K mutation was detected in one primary uveal melanoma, for which the V600E 
assay turned out to be sensitive as well. Direct sequencing of the exon 15 PCR product did not reveal the 
mutations found with the PAP-assay, indicating a low frequency of the mutant allele in primary samples.
CONCLUSIONS. Because of the very sensitive PAP technology, B-RAF mutations were found in cell lines 
and primary uveal melanomas, which suggests that they may occasionally play a role in the activation 
of the MAPK pathway in uveal melanoma and indicates a higher prevalence of B-RAF mutations in uveal 
melanoma than was reported earlier. However, the relative scarcity of the B-RAF mutation excludes an 
elemental role for this mutation in uveal melanoma.





Uveal melanoma is a rare neoplasm arising from melanocytes in the eye, with an incidence rate of 
approximately six to eight new cases per million per year among Caucasians (Egan et al., 1988; Singh 
and Topham, 2003). Approximately 50% of patients who have a medium to large uveal melanoma will 
develop metastatic disease, mostly through hematogenic spread to the liver. Since there is hardly any 
effective treatment for such metastases, they are usually fatal within a year of onset of symptoms. 
Compared with cutaneous melanoma, little is known about the molecular pathogenesis of uveal 
melanoma, and the role of different tumor pathways is less defined. Cutaneous melanoma shares 
the same embryonic origin and similar histologic features, but the mutations that activate the major 
oncogenic pathway in cutaneous melanoma, have not been found in uveal melanoma.
The RAF-MEK-ERK or mitogen-activated protein kinase (MAPK) pathway is of great importance in the 
development of many types of cancer, as well as in melanocytic neoplasia.  In cutaneous melanocytes, 
activation of this pathway has been shown to occur by a variety of mechanisms, including endocrine 
and autocrine growth factor stimulation and mutation of the RAS and RAF genes. Activation of the MAPK 
pathway has also been reported in uveal melanoma, although it only rarely occurs through mutations 
in B-RAF or RAS (Zuidervaart et al., 2005). All B-RAF mutations in cutaneous pigmented neoplasms occur 
within the kinase domain, and the most frequently found mutation in B-RAF consists of a 1799T —› A 
transversion in exon 15, although various other mutations have been described in this exon (Brose et 
al., 2002; Davies et al., 2002; Pollock et al, 2003; Satyamoorthy et al., 2003; Uribe et al., 2003). This T1799A 
mutation is located in the serine/threonine kinase domain of B-RAF, resulting in a valine-to-glutamic acid 
substitution at position 600 (the National Center for Biotechnology Information [NCBI; Bethesda, MD] 
GenBank re-named the V599E mutation based on newly available sequence data; accession number 
NM_004333.2; hereafter referred to as B-RAF V600E), leading to a constitutive activation of proliferation 
signaling (Zhang and Guan, 2000; Wellbrock et al., 2004).
In contrast to these findings, B-RAF mutations have been reported only rarely in uveal melanoma 
(Table 5.1). In 2003, Calipel et al. (Calipel et al., 2003) analyzed four primary uveal melanoma cell lines 
for mutations in the B-RAF gene and reported the presence of the V600E mutation in uveal melanoma 
cell lines OCM-1 and TP-31, of which the mutation in OCM-1 was confirmed in two studies by other 
groups (Calipel et al., 2003; Kilic et al., 2004; Zuidervaart et al., 2005). The same group also reported 
B-RAF mutations in cell lines MKT-BR and SP6.5 (Kilic et al., 2004). To our knowledge, only one B-RAF 
mutation (V600E) has been described in a primary uveal melanoma, (Malaponte et al., 2006) whereas 
several studies reported a lack of B-RAF mutations in cell lines and primary tumors (Cohen et al., 2003; 
Cruz et al., 2003; Edmunds et al., 2003; Rimoldi et al., 2003; Weber et al., 2003; Kilic et al., 2004; Zuidervaart 
et al., 2005). A possible explanation for the apparent lack of B-RAF mutations is that uveal melanomas are 
genetically heterogeneous, and therefore mutations are not present in each cell, similar to our findings 
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in previous studies on the heterogeneous distribution of monosomy of chromosome 3 and methylation 
of RASSF1a (Maat et al., 2007a; Maat et al., 2007b). To detect mutations in a background of normal DNA, 
we used pyrophosphorolysis-activated polymerization (PAP) (Liu and Sommer, 2004) to test whether 
B-RAF mutations are indeed present in uveal melanoma and to test tumor heterogeneity. We set out to 
screen exon 15 of the B-RAF gene in uveal melanoma cell lines and primary tumors with PAP and showed 
that with PAP it is possible to amplify specifically minute amounts of mutant DNA in a background of 
wild-type DNA, and that, consequently, it has a high sensitivity for mutations present in just a small 
number of tumor cells.
Table 5.1. Summary of Published B-RAF Mutation Studies in Uveal Melanoma Cell Lines
Study B-RAF mutation frequency * Cell line with B-RAF mutation
Calipel et al. (2003) 2/4 OCM-1, TP-31
Kiliç et al. (2004) 1/11 OCM-1
Zuidervaart et al. (2005) 1/10 OCM-1
Calipel et al. (2006) 3/3 OCM-1, MKT-BR, SP6.5
This study 2/11 OCM-1, OCM-3
* All V600E mutations
Materials and methods
Cell Lines and Primary Uveal Melanoma Specimens
In total, 11 cell lines derived from primary uveal melanomas (92.1, OCM-1, -3 and -8; Mel-202, -270, -285, 
-290) and uveal melanoma metastases (OMM-1, -2.3, and -2.5) were analyzed for B-RAF mutations. OMM-
2.3 and -2.5 were derived from separate tumor nodules in the liver of the same patient from whom cell 
line Mel-270 was obtained and thus represent a progression model (Chen et al., 1997) All melanoma cell 
lines were cultured in RPMI 1640 medium (Invitrogen-Gibco, Paisley, Scotland, UK) supplemented with 3 
mM L-glutamine (Gibco), 2% penicillin streptomycin and 10% FBS (Hyclone, Logan, UT). All cell cultures 
were incubated at 37°C in a humidified 5% CO2 atmosphere. Archival frozen tumor specimens of primary 
uveal melanoma came from 37 consenting patients who attended the Leiden University Medical Center 
and from eight patients attending the Erasmus Medical Center (Rotterdam, The Netherlands). All tumors 
were primary lesions with a tumor diameter greater than 12 mm and a prominence greater than 6 mm, 
and they had not been treated before enucleation. The validity of the diagnosis of uveal melanoma was 
confirmed histologically in all cases. The research protocol followed the tenets of the current version of 
the Declaration of Helsinki (World Medical Association Declaration of Helsinki 1964; ethical principles for 
medical research involving human subjects).





A column-based extraction kit (Genomic tip 100/G; Qiagen Benelux BV, Venlo, The Netherlands) was 
used to extract DNA from the cell lines and frozen tumor material according to the kit manufacturer’s 
guidelines. A V600E-positive colon carcinoma cell line (HT29) was used as the control (Davies et al., 
2002). DNA concentrations were determined with a spectrophotometer (model ND-1000; NanoDrop 
Technologies Inc., Wilmington, DE).
Table 5.2. Primers
Primer Sequence
PAP - B-RAF - Forward 5’-GTTTTCCTTTACTTAC TACACCTCAGATATATTTCTTCATG-3’
PAP - B-RAF - Reverse 5’-CTGTTCAAACTGATGGGACCCACTCCATCGAGATTTC-dd*T-3’
Sequence – B-RAF exon 15 - Forward 5’-AACTCTTCATAATGCTTGCTCTGATAGG-3’
Sequence – B-RAF exon 15 - Reverse 5’-GCCTCAATTCTTACCATCCACAAAATG-3’
* dd: dideoxy-nucleotide (ddNTP) 
PAP and Sequence Analysis
In the PAP reaction, primers are used that contain a dideoxy-nucleotide (ddNTP) at their 3’ terminus 
and hence cannot be extended. Primers are shown in Table 5.2. A polymerase with pyrophosphorolysis 
activity can remove the dideoxy-nucleotide and thereby activate polymerization. The mutant base 
is resynthesized based on the original template sequence. Since this pyrophosphorolysis activity is 
dependent on double-stranded DNA, only primers that perfectly match the template will be activated 
(Figure 5.1). Because the PAP products are based on resynthesis, mutations can be validated by sequence 
analysis. Amplification was performed on a standard thermal cycler (MJ Research, Watertown, MA) in a 
final volume of 25 µL containing 5 µL 5x PAP buffer (prepared as described by Liu and Sommer (Liu 
and Sommer, 2004)), 0.3 µL (10 picomoles/µL) of each primer (Eurogentec Nederland BV, Maastricht, 
The Netherlands), 0.75 µL KlenTaq-S (ScienTech, St. Louis, MO), 16.65 µL H2O, and 2 µL DNA sample. 
Amplification was initiated by hot start, followed by 50 cycles at 94°C for 15 seconds, 60°C for 40 seconds, 
64°C for 40 seconds, 68°C for 40 seconds, and 72°C for 40 seconds. The product was electrophoresed 
through a standard 2% agarose gel in 1x TBE (0.09 M Tris-borate, 0.002 M EDTA; pH 8.2). The gel was 
stained with ethidium bromide for UV photography by a charge-coupled device camera (G:BOX Chemi; 
Syngene Europe, Cambridge, UK). After gel electrophoresis, DNA bands were excised from the gel, 
purified with a gel extraction kit (Nucleospin Extract II; Macherey-Nagel GmbH & Co., Düren, Germany) 
and sequenced on a DNA sequencing system (Prism 3700 Applied Biosystems [ABI], Foster City, CA). 
Direct sequencing with specific primers (Invitrogen, Breda, The Netherlands) (Table 5.2) was used for 
screening for the B-RAF mutation in all cell lines and primary tumors.
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Figure 5.1. (A) B-RAF exon 15 sequence and primers used in PAP experiments. (B) Situation in which the primer 
with a dideoxy nucleotide (dd*T) at its 3’ end does not match with the normal template and hence will not be 
removed by the phosphorolytic activity of KlenTaq and prevent amplification. (C) Situation in which the primer with 
dd*T-3’ perfectly matches with the mutant template. The phosphorolytic activity of KlenTaq removes the dideoxy 
nucleotide and the primer initiates polymerization. The mutant base is resynthesized based on the template and 
thereby provides a means of validation by sequencing of the PAP product.




Figure 5.2. Sequence analysis of the PAP products showing the sequence of wild-type B-RAF exon 15 (A), the V600E 
mutation (B), and the V600K mutation (C) in primary uveal melanoma DNA samples.
Results
Numerous B-RAF mutations have been detected in primary cutaneous melanomas and their cell lines 
(Brose et al., 2002; Davies et al., 2002; Pollock et al., 2002). In contrast, an extremely low frequency of B-RAF 
mutations in uveal melanoma cell lines and primary tumors has been reported, whereas in vitro studies 
suggest that the B-RAF pathway plays a role in uveal melanoma cell growth (Calipel et al., 2003; Tsao et 
al., 2004; Zuidervaart et al., 2005; Malaponte et al., 2006). Applying PAP on 11 uveal melanoma cell lines 
and 45 primary uveal melanomas, we detected several B-RAF mutations. In cell line OCM-1, the V600E 
mutation was detected, confirming results from previous studies (Table 5.1). Of interest, cell line OCM-
3 seems to harbor the same V600E mutation. Both cell lines were derived from the same laboratory, 
and their melanocytic origin has been demonstrated (Diebold et al., 1997). Several investigators have 
questioned the choroidal origin of cell line OCM-1 based on the presence of the B-RAF V600E mutation, 
which is definitely related to cutaneous melanoma (Kan-Mitchell et al., 1989; Luyten et al., 1996; Kilic et 
al., 2004). Cell lines OCM-1 and -3 showed different HLA-types and confirmed that they were indeed 
derived from different patients and were not interchanged (data not shown). The presence of the 
mutation found in OCM-3 has not been reported before, as far as we know, even though this cell line 
was analyzed in our own laboratory before by conventional sequencing (Zuidervaart et al., 2005).
The fact that direct sequencing reveals a homozygous genotype for the BRAF mutation indicates that 
all cells contain the V600E mutation. In primary uveal melanomas, the V600E mutation in the B-RAF 
gene, which consists of a T —›  A transversion at position 1799 and results in a valine-to-glutamic acid 
substitution, was detected in 6 (13%) of 45 primary tumors. The other mutation uncovered in our 
study was the rarely reported V600K mutation in one primary uveal melanoma sample. This mutation 
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consists of a GT —›  AA substitution at position 1798-1799 and is also located in the serine/threonine 
kinase domain of B-RAF (Pollock et al., 2003). Results were confirmed by sequencing of the PAP product 
after purification from the electrophoresis gel (Figure 5.2). Our primers were not designed to detect 
occurrences of V600D or V600R mutations. We did not detect any differences in tumor size, location, cell 
type or patient survival between tumors with and without the detected V600E mutation.
Discussion
That in this study we detected B-RAF mutations, whereas other studies, including our own (Zuidervaart 
et al., 2005), reported the absence of mutations may be explained by the techniques used. PCR in 
combination with direct sequencing or ligase-detection reaction and mutation assay (Mutector; Biomol, 
Hamburg, Germany) were the techniques used to detect mutations in previous studies (Calipel et 
al., 2003; Cruz et al., 2003; Zuidervaart et al., 2005; Goldenberg-Cohen et al., 2005; Turner et al., 2005). 
However, these techniques are less sensitive than PAP, especially in samples with a low abundance of 
mutations in the presence of excess amounts of wild-type DNA in the tumor (Liu and Sommer, 2004a; 
Liu and Sommer, 2004b) Whereas conventional techniques used to detect mutations theoretically have 
a predicted sensitivity varying between 1:101 to 1:105 PAP has a predicted sensitivity of 1:109 making it 
suitable for the detection of sporadic mutations (Parsons et al., 1997; Liu and Sommer, 2004a). Limited by 
the input of genomic DNA, the practical sensitivity of the essays is lower. For the PAP essay, the practical 
sensitivity is at least 1:104 (Figure 5.3). Also in our study, direct sequencing of exon 15 PCR products 
did not reveal the mutations found with the PAP-assay suggesting a minor frequency for the mutant 
allele, apart from the V600E mutation in cell lines OCM-1 and -3, which could be detected by direct 
sequencing. Although the reverse primer in our PAP-assay is blocked at the 3-prime end, which first 
must be removed to start polymerization, the forward primer will start DNA polymerization each cycle, 
independent of the B-RAF genotype. 
Because of the intrinsic error rate of the forward polymerase reaction, theoretically, an adenine can 
be misincorporated at position 1799. This erroneously synthesized copy can subsequently serve as a 
template for the blocked primer and falsely start a PCR reaction. However, the control assays that we 
performed indicate that the positive PAP-assays with primary tumors are not likely to be explained by 
polymerase artifacts. The assays with normal DNA that we always include in our experiments never 
resulted in a positive PAP assay and thereby suggest that this error rate is limited. Cross contamination 
as cause of positive PAP assays is prevented by using separate rooms before and after PCR. The negative 
controls furthermore indicate that this is not the explanation for the positive tumors, and the latter 
specifically applies to the V600K mutation that we have never detected before. Moreover, dilution 
experiments with OCM-1 and wild-type B-RAF genomic DNA illustrates the sensitivity of the PAP assay 
(Figure 5.3). Under experimental conditions a few mutant copies can be detected in the presence 
of tens of thousands of wild-type copies and supports the hypothesis that uveal melanoma display 




Figure 5.3. The PAP dilution experiment shows the high specificity and sensitivity of this assay. The B-RAF mutation is 
still recognizable in the presence of tens of thousands of wild-type templates.
heterogeneity for B-RAF mutations. Unfortunately, it is not possible to quantify the number of B-RAF 
mutants in a tumor sample with a real time approach because PAP is inhibited by fluorescent dyes 
and the polymerase lacks the 5’—›  3’ exonuclease activity necessary for the TaqMan approach (ABI). 
That to date only PAP is able to detect B-RAF mutations in primary uveal melanoma may indicate that 
cells with mutations are very rare in these tumors and may imply that mutations in B-RAF are not likely 
to drive uveal melanoma development and also adds further proof for the proposed heterogeneity in 
uveal melanoma (Maat et al., 2007a; Maat et al., 2007b). The role of these sporadic mutations remains 
unclear. It may be that the observed B-RAF mutations represent a sign of tumor progression or evolution 
or appear as spontaneous mutations within the developing tumor (Albertson et al., 2003; Duesberg 
et al., 2005). Mutations are found in exons 11 and 15, but only mutations in the activation domain of 
B-RAF such as the V600E are thought to have a selective advantage (Thomas et al., 2007). Of interest, the 
V600E mutation accounts for 92% of the B-RAF mutations detected in cutaneous melanoma samples 
(Davies et al., 2002). However, Pollock (Pollock et al., 2003) reported the presence of B-RAF mutations in 
82% of cutaneous nevi, demonstrating that B-RAF activation alone is insufficient for the development of 
cutaneous melanoma, highlighting the requirement for additional molecular changes. 
In this study, PAP detected B-RAF mutations in uveal melanoma cell lines, as well as in primary tumor 
samples. The PAP assay is sensitive enough to detect a single mutant sequence in excess of wild-type 
DNA sequences. Based on this assay, we conclude that B-RAF mutations occur in uveal melanoma, 
although the clinical relevance of such mutations in a minor percentage of cells has to be determined. 
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Our data reveal that B-RAF mutation frequency in uveal melanoma is higher than earlier anticipated 
and add to the rarely reported B-RAF mutations in uveal melanoma. However, the relative scarcity of the 
B-RAF mutation excludes an elemental role for this mutation in uveal melanoma.
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BACKGROUND. The RAS-RAF-MEK-ERK pathway is involved in the balance between melanocyte 
proliferation and differentiation. The same pathway is constitutively activated in cutaneous and 
uveal melanoma (UM) and related to tumor growth and survival. Whereas mutant B-RAF and N-RAS 
are responsible for the activation of the RAS-RAF-MEK-ERK pathway in most cutaneous melanoma, 
mutations in these genes are usually absent in UM. 
METHODS. We set out to explore the RAS-RAF-MEK-ERK pathway and used mitogen-activated protein 
kinase profiling and tyrosine kinase arrays. 
RESULTS. We identified Src as a kinase that is associated with ERK1/2 activation in UM. However, low 
Src levels and reduced ERK1/2 activation in metastatic cell lines suggest that proliferation in metastases 
can become independent of Src and RAS-RAF-MEK-ERK signaling. Inhibition of Src led to the growth 
reduction of primary UM cultures and cell lines, whereas metastatic cell line growth was only slightly 
reduced.
CONCLUSIONS. We identified Src as an important kinase and a potential target for treatment in primary 
UM. Metastasis cell lines seemed largely resistant to Src inhibition and indicate that in metastases 
treatment, a different approach may be required.





Uveal melanoma (UM) is a rare neoplasm that arises from melanocytes in the eyes. It usually affects 
people in their sixties with an incidence rate of 6–8 new cases per million per year among Caucasians 
(Egan et al., 1988; Singh and Topham, 2003). Little is known about the molecular pathogenesis of UM 
compared with cutaneous melanoma (CM). Cutaneous melanoma and UM share the same embryonic 
origin and similar histological features, but mutations that regulate proliferation and cause a loss of cell-
cycle control in CM can hardly be found in UM. Whereas p16-regulated cell cycle control is targeted by 
the deletion of chromosome 9p or by the mutation of CDKN2A in CM, most of the UM cell lines posses a 
wild-type p16-encoding gene that is, however, not expressed because of the epigenetic modification of 
the CDKN2A gene (van der Velden et al., 2001). The same may be true for the activation of the RAS-RAF-
MEK-ERK or the classical mitogen-activated protein kinase (MAPK) pathway. The MAPK activation is crucial 
for the development of melanocytic neoplasia, and a constitutive activation of this pathway has been 
associated with many different types of cancer (Goding, 2000; Reddy et al., 2003). In CM, the activation 
of the MAPK pathway has been shown to occur by a variety of mechanisms, including autocrine growth 
factor stimulation and mutation of the NRAS (20% of cases) and BRAF (60% of cases) genes (van Elsas et al., 
1995; Davies et al., 2002; Satyamoorthy et al., 2003). The BRAF mutations have only rarely been reported in 
UM and activating mutations in NRAS, which are found in 25% of all cancers, have never been reported 
(Mooy et al., 1991; Soparker et al., 1993; Cohen et al., 2003; Cruz III et al., 2003; Edmunds et al., 2003; 
Rimoldi et al., 2003). However, we and others have found that UM is heterogeneous and that, with more 
sensitive techniques, the percentage of mutant BRAF-positive UM may be higher (Janssen et al., 2008; 
Maat et al., 2008). The lack of mutations in the majority of cells is in contrast with immunohistochemistry 
and western blot analysis, which have shown activation of ERK1/2 in most UM (Rimoldi et al., 2003; Weber 
et al., 2003; Zuidervaart et al., 2005). Nevertheless, the pharmacological inhibition of MAPK/ERK kinases 
1 and 2 (MEK1/2) and the genetic targeting of BRAF with siRNA resulted in a reduced proliferation of UM 
cell lines (Lefevre et al., 2004; Calipel et al., 2006). This indicates that although mutations are absent, the 
RAS-RAF-MEK-ERK pathway is essential for UM growth and suggests that an upstream factor is involved 
in autonomous UM proliferation. Recently, c-Kit was shown to be upregulated in UM and involved in an 
autocrine loop that also involved the RAS-RAF-MEK-ERK pathway (Lefevre et al., 2004). An incomplete 
response to c-Kit inhibition indicates that additional factors are involved (Hofmann et al., 2009). In 
addition, the GNAQ gene was shown to be mutated in almost half of UM (Van Raamsdonk et al., 2008). 
GNAQ is part of the G-protein heterotrimer and represents the GTP-binding part that couples GPCR 
signaling to MAPK activation, which marks it as a potential therapeutic target.
However, targeting downstream signaling molecules may be just as effective as they may be shared 
with other mutant pathways. Tyrosine kinase activity profiling in UM was used to explore the involved 
kinases. On the basis of a UM cell line and two related metastasis cell lines, which revealed reduced 
ERK1/2 activation in metastases, we were able to identify Src as a crucial upstream tyrosine kinase for 
ERK1/2 activation in primary UM. Unfortunately, metastasis cell lines seemed less dependent on Src and 




Cell lines and tumor material
A total of 11 cell lines derived from primary UM (92.1; OCM-1, -3 and -8; Mel-202, -270, -285, -290) 
and UM metastases (OMM-1, -2.3 and -2.5) were analysed for kinase activity (Kan-Mitchell et al., 1989; 
Waard-Siebinga et al., 1995; Luyten et al., 1996; Chen et al., 1997). UM cell lines were cultured in RPMI 
1640 medium (Gibco, Paisley, Scotland) supplemented with 3mM L-glutamine (Gibco), 2% penicillin/
streptomycin and 10% FBS (Hyclone, Logan, UT, USA). Primary UM was cultured in Amniochrome Pro 
Medium (Lonza Group Ltd, Basel, Switzerland). All cell cultures were incubated at 37°C in a humidified 
5% CO2 atmosphere. Cell lysates were obtained by lysing cells in M-PER Mammalian Protein Extract 
Reagent (Pierce, Rockford, IL, USA), supplemented with 1% Halt Protease Inhibitor Cocktail, EDTA-free 
(Pierce) and 1% Halt Phosphatase Inhibitor Cocktail (Pierce). Protein concentrations were measured by 
using the BCA Protein Assay kit (Pierce). Cell lysates were also acquired from three fresh primary UM 
samples obtained by enucleation and from three liver metastases of three different patients, in whom 
the diagnosis was confirmed.
Phospho-MAPK array
The Human Phospho-MAPK Array (R&D Systems, Abingdon, UK) was used to simultaneously detect 
the relative levels of nine MAP kinases and nine other serine/threonine kinases in cell lines, in primary 
UM and in liver metastasis. In this array, capture and control antibodies were spotted in duplicate on 
nitrocellulose membranes. Experiments were carried out according to the manufacturer’s guidelines. 
In short, cell lysates were diluted and incubated with the array. After binding of both phosphorylated 
and unphosphorylated kinases, unbound material was washed away. A cocktail of phospho-site-specific 
biotinylated antibodies was used to detect phosphorylated proteins through streptavidin horseradish 
peroxidase and chemiluminescence. X-ray films of the blots were scanned and analysed using G-boxHR 
(Syngene, Frederick, MD, USA). Control spots with mouse, goat and rabbit antibodies were used for 
background correction.
PamGene tyrosine kinase array
Experiments were carried out using a 4-array semi-automated system (PamStation 4, PamGene, 
’s-Hertogenbosch, The Netherlands) designed for processing PamChip-4 arrays. The PamChip Tyrosine 
Kinase Array (PamGene) contains 144 phospho-peptides, immobilized on a porous microarray surface 
through the peptide N terminus, representing tyrosine kinase substrates. Each array was blocked with 
0.2% bovine serum albumin (BSA), fraction V (Calbiochem Immunochemicals, Merck KGaA, Darmstadt, 
Germany) by pumping it through the porous microarray for 30 cycles of 30 s. Thereafter, each array 
was washed thrice for 8 s with 1x ABL Protein Tyrosine Kinase Reaction Buffer solution (New England 
Biolabs, Ipswich, MA, USA). Next, incubation was carried out at 30°C with the reaction mix, containing 
5 μg cell lysate, 4 μl 100x BSA (New England Biolabs), 0.4 μl 10mM ATP (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) and 0.5 μl 1mg ml-1 monoclonal anti-phosphotyrosine FITC conjugate (clone Py20, 




Exalpha Biologicals, Maynard, MA, USA), adjusted to 40 μl with distilled H
2
O. The sample was pulsed back 
and forth through the porous material for 45 cycles, which is coupled to the base of a well to maximize 
reaction kinetics and to reduce analysis time. At every fifth pump cycle, a 16-bit TIFF image was taken 
with a built-in CCD camera (PamGene). Blocking experiments were carried out with Src family-selective 
tyrosine kinase inhibitors, PP1, PP2 (Biomol International, LP, of Plymouth Meeting, PA, USA) and PP3 
(the inactive analogue, Calbiochem), at an end concentration of 10 μM in line with a large body of 
literature. Each particular inhibitor was mixed with lysates of cell lines and tissue, together with the 
reaction mix just before incubation on the array. Acquired data from the PamStation 4 were captured 
with the supplied software package BioNavigator (Version 0.3.1; PamGene). For the purpose of finding 
differentially phosphorylated substrates, data were imported in the LIMMA package (Bioconductor.org) 
and we applied the empirical Bayes method (Smyth, 2004). Background subtracted data were normalized 
for differences between experiments, and substrates and P-values of 0.05 or less were corrected for 
multiple testing using the Benjamini and Hochberg correction. Substrates with a corrected P-value of 
0.05 or less were assumed to be significant.
Western blot analysis
Cell lysates (10 μg) were separated on 12.5% SDS–PAGE gels, and proteins were transferred to Hybond-
polyvinyldifluoride membranes (Amersham Biosciences, Buckinghamshire, UK). The membranes were 
blocked with 5% skim milk in a PBS-Tween 0.1% solution and probed at room temperature for 1 h 
with antibodies specific to each antigen: phospho-Src (Tyr527; dilution 1:1000), phospho-Src family 
(Tyr416; dilution 1:1000) and Src (36D10; dilution 1:1000) antibody (all from Cell Signaling Technology, 
Hertfordshire, UK). An antibody against actin (Abcam, Cambridge, UK) was used as a loading control. 
Membranes were subsequently incubated at room temperature with horseradish peroxidaseconjugated 
IgG anti-mouse or anti-rabbit secondary antibodies for 1 h. Supersignal West Femto ECL (Pierce) was 
used to visualize protein bands on the membrane.
siRNA treatment
Sub-confluent cell cultures were grown without antibiotics 24 h before transfection in RPMI 1640 
medium. A mixture of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and two different siRNA 
constructs (40 nM) were incubated in the standard medium with reduced serum (1%), according to 
the manufacturer’s instructions. The siRNA constructs (Stealth) were predesigned and validated (≈70% 
knockdown) by the manufacturer (Invitrogen). After 24 and 48 h, the cells were harvested and RNA and 
protein lysates were prepared.
WST-1 assay
Cell proliferation in response to PP1 (10 and 50 μM) was measured by mitochondrial function using 
the WST-1 proliferation reagent (Sigma-Aldrich) as described earlier (Narayanan et al., 2005). This assay 
measures tetrazolium reductase activity in the mitochondria, which serves as a measure of cell viability. 
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In short, 96-well plates were filled with 1250 UM cells per well. At 1 or 3 days (tumor 1–5) and 1 or 6 
days (92.1; OCM-1, -3 and -8; Mel-202, -270, -285, -290, OMM-1, -2.3 and -2.5) after treatment, the WST-1 
reagent was added and absorbance was measured at 450nm on a multiwell spectrophotometer. The 
median and standard error of eight wells were taken at each time and dosage point. 
Quantitative PCR
The cell lines (92.1; OCM-1, -3 and -8; Mel-202, -270, -285, -290, OMM-1, -2.3 and -2.5) were analysed for Src 
gene expression. Primers for Src and the reference gene, β-actin, were developed with Beacon Designer 
software (Premier Biosoft, Palo Alto, CA, USA). Primer sequences for Src: 5’-GCTGCGGCTGGAGGTCAAG-3’ 
(forward) and 5’-AGACATCGTGCCAGGCTTCAG-3’ (reverse). Primer sequence for β-actin: 
5’-CGGGACCTGACTGACTACCTC-3’ (forward) and 5’-CTCCTTAATGTCACGCACGATTTC-3’ (reverse). The 
PCR reaction settings were 95°C for 5 min, then 40 cycles at 96°C for 15 s and at 60°C for 45 s. The DNA 
melting point of the amplicons was acquired by measuring the fluorescence of SYBR Green (Bio-Rad, 
Hercules, CA, USA) during a linear temperature transition from 70 to 97°C at 0.2°C each for 10 s with 
accompanying software (Bio-Rad).
Results
ERK1/2 activation in UM
An antibody array was applied to investigate the MAPK pathway in 10 UM cell lines, in three primary UM 
and three UM metastasis. We observed a uniform HSP27 phosphorylation, with the exception of in three 
UM cell lines (OCM1, -3, -8). UMs displaying activated ERK1/2 as well as phosphorylated HSP27 were 
most common, whereas signals for phosphorylated ERK1/2 were low in metastasis tissue (MET1-3) and 
metastatic UM cell lines (OMM1, OMM2.3 and OMM2.5) (Figure 6.1). Remarkably, two of the metastatic 
cell lines (OMM2.3, OMM2.5) are derived from the same patient as cell line Mel270 but contained far less 
activated ERK1/2.
Differential kinase activity in UM
Reduction of ERK1/2 activation in metastatic cell lines compared with that in primary UM cell lines 
provides a model to identify the underlying mechanism of ERK1/2 activation in the absence of BRAF and 
NRAS mutations. To investigate whether a kinase is differentially activated between primary UM cell lines 
and metastatic UM cell lines, we used peptide-based tyrosine kinase arrays (Lemeer et al., 2007). The UM 
cell lines displayed a high kinase activity, whereas the metastatic UM cell lines displayed a low kinase 
activity, although the same amount of lysate was incubated (Figure 6.2A). After normalisation, we could 
analyse the kinase data and identify nine substrates that were significantly differentially phosphorylated 
between primary and metastatic UM cell lines (Figure 6.2B, Table 6.1.). Primary UM and metastatic tissue 
also showed differential phosphorylation of these nine peptides, although not as clearly as observed in 
the cell lines (Figure 6.2C). 




Figure 6.1. The MAPK activation in primary UM and UM metastases was studied with a MAPK antibody array. We 
observed uniform HSP27 phosphorylation in both cell lines and tissue samples, except in OCM1, -3 and -8 (A). 
Activated ERK1/2 was normalised with HSP27 and shown to be low in UM metastases (MET1-3), whereas metastatic 
cell lines just passed the background (OMM1, -2.3, -2.5) (B).
Table 6.1. Tyrosine kinase substrates on the kinase array that were differentially phosphorylated between primary 
UM cell lines and metastatic cell lines.
Substrate UniProt ID Position Log Fold Change Adj. P value Kinase
CDK2 P24941 T14/Y15 5.3 0.00005 Lyn
FRK P42685 Y387 6.2 0.0002 unknown
SRC8 Q14247 Y499 4.6 0.006 Src
ENOG P09104 Y43 4.7 0.01 Src
EFS O43281 Y253 3.1 0.01 Src
PLCG1 P19174 Y771 4.2 0.01 Syk, Sky, GFRs
CD79A P11912 Y182/Y188 3.1 0.01 Lyn
PAXI P49023 Y118 4.0 0.02 FAK, Src, Brk
PAXI P49023 Y31 4.3 0.03 FAK, Src, Brk
Chapter 6
92
Figure 6.2. Tyrosine kinase activity was measured with an array of peptide substrates. Two representative examples 
of a UM cell line and a metastatic cell line (A). Analysis with eBayes identified nine substrates, representing eight 
proteins, to be significantly (P=0.01) differentially phosphorylated between UM and metastatic cell lines (B). UM (UM1-
3) tyrosine kinase activity is high compared with liver metastasis (MET1-3) (two representative arrays are shown) (C).
Candidate kinase: Src 
We identified nine peptides derived from eight proteins that were differentially phosphorylated 
between primary and metastatic cell line lysates. On the basis of a literature search, we identified 
candidate tyrosine kinases for eight out of nine peptides (Table 6.1) (Cooper et al., 1983; Thomas and 
Brugge, 1997; Koike et al., 2003; Diella et al., 2004). Among the candidates, Src and Src family members 
were most prominent. To validate the candidacy of Src, we performed in vitro inhibition experiments 
with the Src-kinase specific inhibitors PP1 and the PP1 analogue, PP2. We added PP1 and PP2 (10 mM) 
to lysates of primary UM tissue and of a primary UM cell line and measured the inhibitory effect of these 
Src inhibitors using kinase array (Figure 6.3A). A total of seven out of nine substrates that identified Src 
in the first screen displayed a significantly reduced phosphorylation when PP1 or PP2 were added to 
lysates of UM1 and Mel270 (Figure 6.3A). The PLCG1 peptide and one of the PAX1 (Y31) substrates did 
not reach significance but were still phosphorylated at a reduced level after PP1 and PP2 treatments. The 
peptide representing FAK1 Y576/ Y577 is a genuine substrate for Src, which was not detected in the UM 
cell line comparison, but phosphorylation was significantly down regulated by PP1 and PP2 treatments. 
In the control experiment, in which we added the inactive analogue of PP1 (PP3) to cell lysates, we did 
not observe a loss of kinase activity (not shown).
The kinase activity of metastasis tissue and UM tissue differed marginally (Figure 6.2C), and incubation 
with PP1 (10 mM) resulted in a decimation of kinase activity similar to the inhibition that we observed in 
UM tissue (Figure 6.3B). To validate Src activity, Mel270 was transfected with two siRNA constructs that 
target Src and reduced kinase activity (Figure 6.3B).




Figure 6.3. UM1 (06-12) and Mel270 treatment with Src inhibitors (PP1/PP2) identified eight substrates with a 
significant reduction in phosphorylation (A). The inhibition of EFS peptide phosphorylation by genetic (Src siRNA) 
and pharmacological means (PP1) in cell line Mel270, and PP1 treatment of cell lysates of UM (UM1) and metastasis 
tissue (MET3) (B).
A	   B 	  
Figure 6.4. ERK1/2 activation in Mel270 24 and 48 h after transfection with Src siRNA. Phosphorylated HSP27 is 
included as reference signal.
Regulation of ERK1/2 and growth
To investigate whether Src contributes to ERK1/2 activation in Mel270, we analysed the two Src siRNA-
transfected cell cultures with the MAPK antibody array. At 24 and 48 h after transfection with Src siRNA, 
we observed a reduced ERK1 phosphorylation, whereas ERK2 phosphorylation was minimally affected 
(Figure 6.4). Whether Src inhibition and consequently a lowered ERK activation in UM cell lines is 
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associated with a reduced growth was investigated with the WST-1 viability assay (Figure 6.5). All UM cell 
lines showed a PP1-dose and time (1–6 days)-dependent reduction in cell viability but the magnitude of 
the response differed widely. In general, the metastatic UM cell lines were less affected by PP1. We also 
determined the growth inhibition rate of PP1 in cultures of five primary UM cell cultures and observed 
an increased sensitivity to PP1 treatment compared with the cell lines. We had to take samples at day 3 
of PP1 treatment because, thereafter, massive cell death occurred (Figure 6.5B). 
Src protein is reduced in metastasis cell line 
Src is regulated by the phosphorylation of tyrosine residues at position 416 (Y416) and 527 (Y527). The 
expression of phosphorylated Src Y416, which is associated with an active conformation, was low in the 
metastatic UM cell lines (Figure 6.6A). Surprisingly, the phosphorylation of Y527, which is associated with 
an inactive conformation, was also low, and a subsequent analysis indicated that Src expression is low in 
metastatic UM cell lines. Therefore, the difference between kinase activity in metastatic cell lines (OMM1, 
OMM2.3 and OMM2.5) and UM cell lines (OCM1, OCM3, OCM8, Mel202, Mel270, Mel285, Mel290 and 
92.1) seems to be the result of a difference in Src expression.
Figure 6.5. UM cell lines and primary cultures were cultured with PP1 (10 mM and 50 mM). After 24 h and at 3 
days (UM cultures) and 6 days (cell lines), viability was tested with the WST-1 assay. Two representative cell culture 
experiments for which all time points and conditions are shown (A). Growth inhibition by PP1 (50 mM) after 24 h and 
at 3 and 6 days was normalised to the control culture of each individual cell line (B).







































To investigate the origin of a lowered Src expression, we performed a gene expression analysis (Figure 
6.6B). Src gene expression varied widely in the cell lines and in the metastatic cell lines, but a correlation 
between protein and gene expression was not observed in UM cell lines. A western analysis of Src 
expression in UM and metastasis tissue revealed a very high Src expression in only one out of three 
primary UM, whereas all three metastasis tissues displayed medium expression of Src protein (Figure 
6.6C).
Figure 6.6. Western analysis of Src in the UM cell lines for activating phosphorylation (Y416), inactivating 
phosphorylation (Y527) and total Src expression (A). Src gene expression measured by qPCR varied widely but did 
not correlate with a variation in protein expression (B). UM and metastasis tissue all displayed a medium Src kinase 
































































































































Constitutive activation of ERK1/2 has often been reported for UM (Rimoldi et al., 2003; Weber et al., 2003; 
Zuidervaart et al., 2005). Using a more quantitative approach, we distinguished a decrease in active 
ERK1/2 in metastatic cell lines and in fresh liver metastasis, suggesting a loss of ERK1/2 activation during 
UM progression. The latter is unexpected as ERK1/2 activation is generally associated with mitogen 
signalling and is known to determine malignant potential in vitro. However, in endometrial and breast 
cancer, ERK1/2 activation has been associated with a good prognosis (Milde-Langosch et al., 2005; 
Mizumoto et al., 2007). A possible explanation is provided by the observation that ERK1/2 is involved 
in oncogene and stress-induced senescence (Serrano et al., 1997; Stott et al., 1998). This mechanism is 
thought to be an important defense for cells that are at risk of neoplastic transformation and need to 
be circumvented by tumor cells in order to proliferate. Loss of activated ERK1/2 may not only relieve the 
associated inhibitory mechanisms in a direct manner but may also require alternative mitogenic signals 
to take over in UM metastasis.
Metastatic and UM cell lines provide a unique model to identify the mechanisms that regulate ERK1/2 
activation in UM. Earlier work already showed that ERK1/2 phosphorylation in UM depends on the MAPK 
pathway, although mutations in the usual suspects (e.g., BRAF and NRAS) are lacking (Calipel et al., 2006). 
We investigated the possibility of a tyrosine kinase with differential activities in UM and UM metastasis 
to be responsible for ERK1/2 activation, using an array of kinase activity assays. Src was revealed as a 
differentially activated tyrosine kinase and this was supported by incubation with Src-specific kinase 
inhibitors, PP1 and PP2. Moreover, by treating cell lysates instead of cell cultures, we minimized the 
secondary effects of the inhibitors. However, PP1 and PP2 affect most of the Src family of tyrosine 
kinases, and the observed reduction in kinase activity therefore does not specifically mark Src. Multi-
target inhibitors are a problem in molecular analysis but may be beneficial in clinical application, as, 
in CM, a switch from Src to Yes signalling has been reported in brain metastases (Summy and Gallick, 
2003). To specifically inhibit Src, we targeted the Src gene expression with a siRNA approach. We 
detected a reduced kinase activity in Mel270 on transfection and this was correlated with a reduced 
ERK1 activation. The ERK2 activation seemed unaffected, which could be because of the limited efficacy 
of siRNA treatment, or it could indicate the activity of another, yet unidentified, kinase. A low Src 
protein expression in conjunction with a loss of ERK1/2 activation in metastatic UM cell lines, however, 
supports the hypothesis that, in UM, Src kinase is involved in ERK1/2 activation. Gene expression analysis 
revealed no significant differences between metastatic and UM cell lines, and thereby indicated that 
posttranscriptional mechanisms are most likely involved in Src down regulation. Src is both a kinase 
as well as a client protein for the chaperone HSP90 that is expressed in UM (Missotten et al., 2003). 
Whether HSP90 is reduced in metastases and whether treatment with HSP90 inhibitors depends on 
Src signalling is part of future investigation (Babchia et al., 2008; Faingold et al., 2008). The inhibition of 
Src kinase activity resulted in a strong growth reduction in all UM cultures, whereas in UM cell lines, the 
response varied more widely. The genetic background of the cell lines might play a role in the observed 




variation. However, all UM cell lines displayed Src kinase activity and PP1 sensitivity, irrespective of c-kit 
upregulation (Mel270) or the BRAF V600E (OCM1) and GNAQ Q209L (Mel202) mutation status (Lefevre 
et al., 2004; Van Raamsdonk et al., 2008). Tissue of UM and UM liver metastasis displayed more or less 
comparable Src levels. The incubation of lysates with Src inhibitors resulted in a comparable reduction 
of kinase activity in UM and metastasis tissue. The possibility that there exist Src negative clones in liver 
metastasis can, however, not be ruled out on the basis of these data. Clinical trials targeting Src kinase 
activity in UM should therefore anticipate this potential risk.
In conclusion, we have identified a differential ERK1/2 activation in UM and metastatic UM cell lines. 
Using tyrosine kinase activity profiling, we identified Src as a determinant of ERK1/2 activation and 
showed that Src expression and kinase activity, together with ERK1/2 activation, are reduced in UM 
metastases cell lines.
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Introduction
At present, molecular testing of uveal melanoma has developed to such a level that one can predict the 
prognosis of the patient with great accuracy. The course of the clinical disease or patient survival has not 
been altered, because effective treatment regimens against metastatic disease or measures to prevent 
progress are at present lacking. In order to treat or prevent growth of metastases, we need to understand 
the molecular pathways underlying uveal melanoma tumor development and tumor progression. The 
aim of this thesis is therefore to characterize the molecular mechanisms and the pathways that drive 
tumor growth and progression in uveal melanoma.
Molecular markers
Monosomy 3 was the first recognized molecular predictor of metastatic disease (Sisley et al., 1990; 
Horsthemke et al., 1992; Prescher et al., 1995; White et al., 1998). The possibility to identify patients 
at high risk of developing metastases makes intense monitoring of these patients useful, and may 
improve early detection and treatment of metastatic disease. Hence, tumor tissue should be available 
for prognostification. For patients treated with enucleation, tumor tissue is readily available. However, 
patients are preferably treated with an eye-conserving therapy that does not generate tumor tissue 
for analysis. Alternatively, a tumor sample can be obtained by fine needle aspiration biopsies (FNABs) 
from the tumor base by a scleral approach, or from the apex of the tumor via a transvitreal approach. 
Chromosome analysis and gene expression analysis of the tumor FNAB can be used to identify patients 
at risk. 
This approach relies on the assumption that uveal melanomas represent a genetically homogeneous 
entity. In Chapter 2, we tested this assumption by analyzing tumor heterogeneity. We showed that 
some uveal melanomas are heterogeneous for the number of copies of chromosome 3: while one area 
of the tumor may show monosomy 3, another may not. Since then, other studies have confirmed tumor 
heterogeneity in uveal melanomas and a follow-up study showed that any number of cells with loss of 
chromosome 3 is associated with a bad prognosis (Bronkhorst et al., 2011). This implies that one may 
miss cells with monosomy 3 in uveal melanoma if they occur in low numbers. A negative test on a 
biopsy therefore does not exclude the presence of monosomy 3 somewhere else in the tumor. 
More recently, disparate results for samples obtained from the tumor base and the apex were revealed 
(Schoenfield et al., 2009). This confirmed the presence of heterogeneity in uveal melanoma and 
illustrated the potential risk for the analysis of biopsies. An additional study showed that one in ten uveal 
melanomas overall and one in five melanomas that were less than 3.5 mm in thickness seemed to be 
heterogeneous when sampled from more than one location (Augsburger et al., 2008). Before prognostic 
biopsies become everyday clinical practice, procedures should be developed to minimize false negative 
testing (Kivelä et al., 2009).
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Methylation analysis
The correlation of monosomy 3 with decreased survival and metastatic disease may imply the presence 
of a tumor suppressor gene at this chromosome (Prescher et al., 1996; Kilic et al., 2005). Assessment 
of minimally deleted regions in malignant uveal melanoma has helped to identify two susceptibility 
regions (Tschentscher et al., 2001; Parella et al., 2003). Tumor suppressor genes have not been identified 
at these loci but proximal of the 3p25 locus, the Bap1 (3p21.1) gene has very recently been identified as 
a tumor suppressor gene (Harbour et al., 2010). A tumor suppressor role was furthermore supported by 
germline Bap1 mutations that predispose to mesothelioma and melanocytic malignancies (Wesner et 
al., 2011; Testa et al., 2011). In virtually the same region as Bap1, we identified the RASSF1 (Ras association 
domain family 1) gene (3p21.3) as a potential tumor suppressor gene that is silenced by methylation in 
uveal melanoma (Maat et al., 2007).
Hypermethylation of promoter-associated CpG islands has emerged as an important epigenetic 
mechanism leading to the transcriptional silencing of tumor suppressor genes in cancer development, 
including the development of uveal melanoma (Jones and Baylin, 2002; van der Velden et al., 2001; van 
der Velden et al., 2003; van Dinten et al., 2005). Studies on other malignancies have identified the RASSF1 
gene, located on chromosome 3p21.3, as an important regulator of cell proliferation (Hamilton et al., 
2005; Pfeifer and Dammann, 2005; Choi et al., 2006). Hypermethylation of the CpG island in the promoter 
region of a major alternative transcript of this gene, RASSF1a, occurs frequently in various carcinomas, 
including those of the breast, prostate, and lung, and in cutaneous malignant melanoma (Spugnardi et 
al., 2003; Kang et al., 2004; Yeo et al., 2005; Fukasawa et al., 2006). In chapter 3 we performed methylation 
analysis of uveal melanoma cell lines, primary tumor tissue and metastases. This analysis revealed a 
methylated promoter region of RASSF1a in 50% of primary tumors. Part of the primary samples and a 
metastatic lesion showed methylated as well as unmethylated DNA in the same sample, indicating tumor 
heterogeneity. Development of metastatic disease correlated with the presence of a hypermethylated 
RASSF1a promoter region. It has been suggested that the RASSF1a protein acts at the level of cell cycle 
control and mitosis but also in apoptosis checkpoints (Shivakumar et al., 2002). Recently it was shown 
that ectopic expression of RASSF1a in uveal melanoma results in senescence while depletion of RASSF1a 
in uveal melanocytes promotes proliferation (Calipel et al., 2011). Loss of expression of RASSF1a in uveal 
melanoma due to hypermethylation and monosomy 3 may therefore promote tumor development by 
escaping cell cycle control and promoting mitosis.
Epigenetic regulation of RASEF, a potential tumor-suppressor gene in uveal melanoma
An alternative for the analysis of somatic changes in tumors is the analysis of the germline in families 
that display a predisposition to uveal melanoma development. While in cutaneous melanoma, 
familial occurrence is a well-known phenomenon; familial occurrence of uveal melanoma is quite 
rare. However, families presenting both cutaneous and uveal melanomas without a genetic link to the 
familial melanoma locus at 9p21 may represent a different syndrome. Linkage analysis in such uveal and 
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cutaneous melanoma families identified the 9q21 region as a locus for a potential tumor suppressor 
gene involved in the development of hereditary melanoma (Jönsson et al., 2005). In addition, LOH 
analysis in two uveal melanomas from members of the families in which linkage was identified indicated 
9q21 to be the possible region for a tumor suppressor gene. The 9q21 region harbors the RASEF gene, 
which is potentially involved in the RAS pathway that is prominent in the development of melanoma 
(Padua et al., 1984; Rimoldi et al., 2003). 
In Chapter 4 we analyzed the RASEF gene for mutations and in line with the findings of Jönsson et al., we 
did not detect any mutations in the RASEF gene other than a known single nucleotide polymorphism 
(SNP) (Sweetser et al., 2005). Our data indicated that tumors often showed heterogeneity with regard 
to methylation of the RASEF gene. The combination of a homozygous genotype (TT) and a methylated 
RASEF gene was associated with death due to metastases. Cell lines that did not express RASEF contained 
a methylated promoter, whereas all cell lines with expression lacked this methylation, confirming 
epigenetic regulation. The primary uveal melanomas displayed heterogeneity for RASEF methylation but 
never reached levels above ~ 50% methylation, and most commonly only a part of the CpG’s present in 
the promoter region was methylated. We conclude that homozygosity in combination with methylation 
is the mechanism that targets RASEF in uveal melanoma, appointing RASEF as a bona fide tumor 
suppressor that is epigenetically silenced in uveal melanoma. Allelic imbalance at this locus supports 
a tumor-suppressor role for RASEF; however, analysis of RASEF in proliferation, survival, and migration of 
uveal melanoma is needed to confirm this. 
Mitogen-activated protein kinase (MAPK) pathway
Another candidate uveal melanoma gene at 9q21 is the GNAQ gene that was found to be mutated in 
almost half of the uveal melanoma (Van Raamsdonk et al., 2009). GNAQ is part of the heterotrimeric 
G-protein and represents the GTP-binding part that couples GPCR intracellular signaling. Recently also 
the homolog of GNAQ, i.e. GNA11, was shown to be mutated in a large portion of the uveal melanoma 
that did not contain a GNAQ mutation (van Raamsdonk et al., 2010). GNAQ and GNA11 are most likely 
to signal via protein kinase C and will lead to activation of the RAF-MEK-ERK or mitogen-activated 
protein kinase (MAPK) pathway (Patel et al., 2011). The MAPK pathway plays an important role in the 
development of many types of cancer, as well as in melanocytic neoplasia (Davies et al., 2002; Cohen et 
al., 2003). 
In cutaneous melanocytes, activation of the MAPK pathway has been shown to occur by a variety of 
mechanisms, including endocrine and autocrine growth factor stimulation and mutation of the N-RAS 
and B-RAF genes. In contrast to these findings, B-RAF mutations have been reported only rarely in uveal 
melanoma. A possible explanation for this apparent lack of B-RAF mutations is that uveal melanomas 
are genetically heterogeneous, and therefore mutations are not present in each cell, similar to our 
findings in previous studies on the heterogeneous distribution of monosomy of chromosome 3 and 
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methylation of RASSF1a (see Chapter 2 and Chapter 3). To detect mutations in a background of normal 
DNA, we used pyrophosphorolysis-activated polymerization to investigate whether B-RAF mutations 
are indeed present in uveal melanoma and to test tumor heterogeneity. In Chapter 5 we conclude 
that B-RAF mutations occur in uveal melanoma, although the clinical relevance of such mutations in a 
minor percentage of cells still has to be determined. Our data reveal that the B-RAF mutation frequency 
in uveal melanoma is higher than earlier anticipated and add to the rare reports on B-RAF mutations in 
uveal melanoma. The relative scarcity of the B-RAF mutation excludes an elemental role for this mutation 
in uveal melanoma. 
Tyrosine kinase activity profiling
Fairly little is known about the molecular pathogenesis of uveal melanoma as compared to cutaneous 
melanoma and with the detection of the GNAQ and GNA11 mutations, the question remains how these 
mutations stimulate proliferation. Activation of the classical MAPK pathway is seen in many types of 
cancer and activation of this RAS-RAF-MEK-ERK route may well be essential in stimulating cell division in 
uveal melanoma too. Analysis with immunohistochemistry and western blot showed activation of ERK1/2 
in most uveal melanomas, supporting the idea of activation of the MAPK pathway (Rimoldi et al., 2003; 
Weber et al., 2003; Zuidervaart et al., 2005). Also, the pharmacological inhibition of MAPK/ERK kinases 
1 and 2 (MEK1/2) and the genetic targeting of B-RAF with siRNA resulted in a reduced proliferation of 
uveal melanoma cell lines (Levefre et al., 2004; Calipel et al., 2006). This indicates that although mutations 
are absent in this pathway, RAS-RAF-MEK-ERK signaling is essential for uveal melanoma growth and 
suggests that an upstream factor is involved in autonomous uveal melanoma proliferation. 
In chapter 6 we analyzed mechanisms involved in RAS-RAF-ERK activation in cell lines with differential 
ERK activation. We compared a uveal melanoma cell line, obtained from a primary uveal melanoma, 
with two cell lines derived from two metastases from the same patient. Compared to the primary uveal 
melanoma cell line, the two metastatic cell lines displayed a reduced ERK1/2 activation. We were able to 
identify Src as a crucial upstream tyrosine kinase for ERK1/2 activation in the primary uveal melanoma. 
In order to validate the candidacy of Src as regulator, we applied genetic (siRNA) and pharmaceutical 
inhibitors of Src. A strong reduction of active ERK1 was observed in conjunction with marked growth 
inhibition.
Most uveal melanomas present mutations in the GNAQ and GNA11 genes that are correlated with 
MAPK activation (van Raamsdonk et al., 2009). We identified Src as a crucial upstream tyrosine kinase 
for ERK1/2 activation in uveal melanoma and hence Src is expected to be involved in GNAQ/GNA11 
signaling. Reduced ERK1/2 activation in metastatic cell lines and in fresh liver metastases suggests a loss 
of ERK1/2 activation during uveal melanoma progression. The latter is unexpected, as ERK1/2 activation 
is generally associated with malignant potential in vitro. However, in endometrial and breast cancer, 
ERK1/2 activation has been associated with a good prognosis (Milde-Langosch et al., 2005; Mizumoto et 
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al., 2007). A possible explanation is provided by the observation that ERK1/2 is involved in oncogene and 
stress-induced senescence (Serrano et al., 1997; Stott et al., 1998). This mechanism is thought to be an 
important defense for cells that are at risk of neoplastic transformation and need to be circumvented by 
tumor cells in order to proliferate. Loss of activated ERK1/2 may not only relieve the associated inhibitory 
mechanisms in a direct manner but may also require alternative mitogenic signals to take over in uveal 
melanoma metastasis. Overall, we can conclude that Src is a differentially activated tyrosine kinase and 
that the Src family plays an important role in cell proliferation in primary uveal melanoma. 
Future studies
Identifying the molecular pathways that are involved in proliferation of uveal melanoma may lead to 
effective therapies of metastases of this malignancy. The identification of mutations such as GNAQ and 
GNA11 that may initiate tumor growth, and unraveling the molecular basis of the association between 
loss of chromosome 3 and metastasis formation may assist in the selection of new drugs. Furthermore, 
as shown in this thesis, tumors are quite often heterogeneous en not all cells from the primary tumor 
may react in the same way. Additionally, cells that are present in metastases may be a subclone of the 
primary tumor and have different characteristics.
Using material from the patient’s primary tumor and metastases may be essential to determine that 
tumor’s specificity to new treatments, leading to individual targeted therapies, to obtain long-term 
survival.
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Introductie
Met behulp van moleculair onderzoek is het mogelijk om met een grote mate van nauwkeurigheid 
de prognose van patiënten met een oogmelanoom te bepalen. Ondanks deze vooruitgang is het 
beloop van de ziekte of de duur van de overleving van de patiënt nauwelijks verbeterd, omdat een 
effectieve therapie tegen uitzaaiingen of de mogelijkheid om uitzaaiingen te voorkomen, ontbreekt. 
Om dit te kunnen veranderen is kennis vereist over de manier waarop deze tumoren groeien en hoe ze 
kunnen uitzaaien ofwel metastaseren. Het doel van dit onderzoek was daarom om de mechanismen die 
betrokken zijn bij de ontwikkeling van een oogmelanoom beter te begrijpen.
Moleculaire markers
Monosomie 3, ofwel het verlies van één kopie van chromosoom 3 was de eerste moleculaire voorspeller 
van metastasering (Sisley et al., 1990; Horsthemke et al., 1992; Prescher et al., 1995; White et al., 1998). 
De mogelijkheid om patiënten die een hoog risico lopen om uitzaaiingen te ontwikkelen te selecteren 
voor frequente controle, maakt vroegdetectie van metastasen en eerdere behandeling mogelijk. Voor 
vroegopsporing is echter wel tumormateriaal nodig voor analyse. Voor patiënten die behandelend 
worden door middel van verwijdering van de oogbol is dit geen probleem, maar voor de patiënten 
die behandeld worden met oog-sparende therapie zoals lokale bestraling, is tumormateriaal niet 
voorhanden. Een alternatieve manier om toch tumorweefsel in handen te krijgen en een uitspraak over 
risico of prognose te kunnen doen, is door middel van het nemen van een biopt met een dunne naald 
(FNAB; Fine Needle Aspiration Biopsy). 
Deze aanpak berust op de aanname dat oogmelanomen een genetisch homogene eenheid vormen. 
In hoofdstuk 2 van dit proefschrift hebben we deze aanname onderzocht en aangetoond dat 
oogmelanomen ook heterogeen kunnen zijn wat betreft de verdeling van chromosoom 3: In het ene 
gebied kan een kopie verloren zijn gegaan, terwijl dat in het ander gebied of gedeelte van de tumor niet 
het geval is. Sinds deze bevinding zijn er meerdere studies geweest die deze heterogeniteit bevestigd 
hebben en een follow-up studie heeft laten zien dat de aanwezigheid van cellen met maar één kopie 
van chromosoom 3, hoe beperkt dat aantal ook kan zijn, toch geassocieerd wordt met een slechte 
prognose (Bronkhorst et al., 2011). Dit betekent dat je deze cellen kunt missen en dat een negatieve 
testuitslag van een biopt de aanwezigheid van deze cellen in de tumor, niet uitsluit. Voordat deze 
zogenaamde prognostische biopten in de praktijk kunnen worden aangeboden zullen er eerst goede 
manieren moeten worden gevonden om fouten te minimaliseren (Kivelä et al., 2009).
Methylatie onderzoek
De correlatie tussen monosomie 3 en de beperkte overleving door uitzaaiingen, kan betekenen dat er 
zich op chromosoom 3 een tumor-suppressor gen bevindt (Prescher et al., 1996; Kilic et al., 2005). Twee 
gebieden werden hiervoor aangewezen, maar er werden geen tumor-suppressor genen geïdentificeerd 
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(Tschentscher et al., 2001; Parella et al., 2003). Net naast één van deze gebieden werd recent het Bap1 
(3p21.1) gen ontdekt (Harbour et al., 2010). In ongeveer dezelfde regio identificeerden wij het RASSF1 
gen (Ras association domain family 1), dat uitgeschakeld wordt door middel van methylatie (Maat et 
al., 2007). Hypermethylatie van CpG eilanden in de promotorregio van tumor suppressor genen en 
onderdrukking van expressie heeft zich ontwikkeld tot een belangrijk epigenetisch mechanisme in de 
ontwikkeling van kanker dat ook in oogmelanomen is beschreven (van der Velden et al., 2001; Jones and 
Baylin, 2002; van der Velden et al., 2003; van Dinten et al., 2005). 
Hypermethylatie van CpG eilanden in de promotor regio van een belangrijk alternatief transcript van dit 
gen, RASSF1a, wordt  in verschillende carcinomen gevonden (Spugnardi et al., 2003; Kang et al., 2004; Yeo 
et al., 2005; Fukasawa et al., 2006). In hoofdstuk 3 wordt aangetoond dat een gemethyleerd RASSF1a in 
50% van de primaire tumoren voorkomt en dat dit correleert met de ontwikkeling van uitzaaiingen. Een 
deel van de primaire monsters en een uitgezaaide laesie vertonen tumor heterogeniteit en presenteren 
zowel ongemethyleerd, als gemethyleerd DNA in hetzelfde monster. Er zijn aanwijzingen dat het RASSF1a 
eiwit de celcyclus controleert en dat verlies dientengevolge de celdeling kan bevorderen (Shivakumar 
et al., 2002; Hamilton et al., 2005; Pfeifer and Dammann, 2005; Choi et al., 2006; Calipel et al., 2011). 
Epigenetische regulatie van RASEF
 Een alternatief voor de analyse van somatische veranderingen in tumoren, is de analyse van het erfelijk 
materiaal in gezinnen die een predispositie voor oogmelanomen hebben. Terwijl in huidmelanomen 
het familiair voorkomen een bekend fenomeen is, is het familiair voorkomen van oogmelanomen 
vrij zeldzaam. Er bestaan echter families waar zowel huid- en oogmelanomen voorkomen, die niet 
in verband staan met het familiair melanoom locus op 9p21. Linkage-analyse in deze oog- en huid-
melanoom families wijzen de 9q21 regio aan als een locus voor een mogelijke tumor suppressor gen dat 
betrokken is bij de ontwikkeling van het erfelijke melanoom. Daarnaast identificeert heterozygotie (LOH) 
analyse in twee oogmelanomen, de 9q21 regio als mogelijke omgeving voor een tumor suppressor gen 
(Jönsson et al., 2005). 
Deze regio herbergt het RASEF-gen, dat mogelijk betrokken is in de RAS-pathway, die prominent 
aanwezig is in de ontwikkeling van melanomen (Padua et al., 1984; Rimoldi et al., 2003). In hoofdstuk 4 
hebben we het RASEF gen onderzocht voor mutaties en in overeenstemming met de bevindingen van 
Jönsson et al., konden wij geen mutaties detecteren in het gen, anders dan een bekend polymorfisme 
(Jönsson et al., 2005;. Sweetser et al., 2005). Epigenetische regulatie was echter aanwezig en cellijnen 
zonder RASEF expressie bleken een gemethyleerd gen te bevatten.
Onze resultaten met tumorweefsel gaven aan dat tumoren vaak heterogeen zijn met betrekking 
tot methylatie van het RASEF gen. Integratie van genetische en epigenetische analyse toonde aan 
dat de combinatie van een homozygoot genotype en een gemethyleerd RASEF gen, geassocieerd 
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was met overlijden als gevolg van uitzaaiingen. Wij hypothetiseren dat in oogmelanomen verlies 
van een allel, in combinatie met methylering, het mechanisme is dat RASEF kan uitschakelen. 
Allelische imbalans op dit locus ondersteunt een tumor-suppressor rol voor RASEF, maar verdere 
analyse van RASEF in zowel proliferatie, overleving en metastasering is nodig om dit te bevestigen. 
 
Mitogen-activated protein kinase (MAPK) route
Een ander kandidaat melanoom-gen op 9q21 is het GNAQ gen, dat in bijna de helft van de oogmelanomen 
gemuteerd is (Van Raamsdonk et al., 2009). GNAQ is onderdeel van een complex eiwit dat mede zorg 
draagt voor intracellulaire signalering. Recent bleek dat ook de homoloog van GNAQ, GNA11 genaamd, 
een mutatie bevat in de oogmelanomen die geen GNAQ mutatie bezitten (van Raamsdonk et al., 2010). 
GNAQ en GNA11 signaleren via Protein-kinase C (PKC) en dit zou kunnen resulteren in activatie van de 
MAPK (mitogen-activated protein kinase) route (Patel et al., 2011). De MAPK route speelt een belangrijke 
rol in de ontwikkeling van vele vormen van kanker en dit geldt ook voor de tumoren die afstammen van 
melanocyten (Davies et al., 2002;. Cohen et al., 2003). 
In melanocyten van de huid vindt activatie van de MAPK route plaats door een verscheidenheid van 
mechanismen, waaronder stimulatie door groeifactoren en mutatie van de N-RAS en B-RAF genen. 
Mutaties in B-RAF die kenmerkend zijn voor huidmelanomen worden slechts zelden aangetroffen in 
oogmelanomen (Calipel et al., 2003; Kiliç et al., 2004;. Zuidervaart et al., 2005; Calipel et al., 2006). Een 
mogelijke verklaring voor het schijnbare gebrek aan B-RAF mutaties is dat oogmelanomen genetisch 
heterogeen zijn en de mutaties waarschijnlijk niet in elke cel aanwezig zijn. Dit is vergelijkbaar met onze 
bevindingen in eerdere onderzoeken naar de heterogene verdeling van monosomie van chromosoom 
3 en methylatie status van het RASSF1a gen (hoofdstuk 2 en hoofdstuk 3). Om te onderzoeken of B-RAF 
mutaties, eventueel in een achtergrond van normaal DNA, inderdaad aanwezig zijn in oogmelanomen 
en om de heterogeniteit van de tumor te onderzoeken, gebruikten we een zeer gevoelige mutatie 
specifieke PCR (pyrophosphorolysis-geactiveerde polymerisatie; PAP). In hoofdstuk 5 concluderen we 
dat B-RAF mutaties, frequenter dan aangenomen, voorkomen in oogmelanomen. Hoewel de klinische 
relevantie van deze B-RAF mutaties in een klein percentage van de tumorcellen nog nader moet worden 
bepaald, lijkt de relatieve schaarste van B-RAF mutatie bevattende cellen, een belangrijke rol voor deze 
mutatie in oogmelanomen uit te sluiten.
 
Tyrosine kinase-activiteit 
In vergelijking met het huidmelanoom is er vrij weinig bekend over de moleculaire pathogenese van 
oogmelanomen. Ook met de detectie van GNAQ en GNA11 mutaties, blijft het de vraag hoe deze 
mutaties de proliferatie precies stimuleren. Activatie van de klassieke MAPK route is te zien in vele 
soorten van kanker en activatie van deze route is vermoedelijk van essentieel belang bij de stimulatie 
van de celdeling in het oogmelanoom (Rimoldi et al., 2003; Weber et al., 2003; Zuidervaart et al., 
2005). Remming van de MAPK route met farmacologische en genetische middelen resulteerde in een 
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verminderde proliferatie van oogmelanoom-cellijnen (Levefre et al., 2004; Calipel et al., 2006). Dit geeft 
aan dat, hoewel mutaties in deze route afwezig zijn, MAPK signalering essentieel is voor groei van het 
oogmelanoom en suggereert tevens dat een in de route hoger gelegen factor betrokken is bij de 
proliferatie van deze tumoren.
In hoofdstuk 6 analyseerden we het mechanisme dat betrokken is bij MAPK-activering in oogmelanoom 
cellijnen. We vergeleken een oogmelanoom-cellijn verkregen uit een primair oogmelanoom met 
twee cellijnen afkomstig van twee uitzaaiingen van dezelfde patiënt. In vergelijking met de primaire 
oogmelanoom-cellijn, vertoonden de twee gemetastaseerde cellijnen een verminderde MAPK activiteit. 
We waren in staat om Src te identificeren als een cruciale hoger gelegen tyrosine kinase betrokken bij 
MAPK activatie in het primaire oogmelanoom. Om de bevindingen te valideren, pasten we genetische 
remming (siRNA) en farmaceutische remming van Src toe. Een sterke vermindering van MAPK activatie 
en celgroei werden waargenomen en bevestigden daarmee de rol van Src in oogmelanomen. 
 
Verminderde MAPK activatie in gemetastaseerde cellijnen en in verse levermetastasen duidt op een 
verlies van MAPK activatie bij de progressie van het oogmelanoom. Dit laatste is onverwacht, omdat 
MAPK activatie over het algemeen geassocieerd is met het maligne karakter van tumorcellen. Echter, in 
sommige tumoren zoals endometrium-en borstkanker, wordt MAPK activatie ook in verband gebracht 
met een goede prognose (Milde-Langosch et al., 2005; Mizumoto et al., 2007). Een mogelijke verklaring 
wordt geleverd door de observatie dat de MAPK route betrokken is bij oncogen en stress-geïnduceerde 
cel-inactivatie (senescence) (Serrano et al., 1997; Stott et al., 1998). De gedachte is, dat dit mechanisme 
een belangrijk verdedigingsmechanisme is voor cellen die risico lopen om te ontaarden, dat omzeild 
moet worden door de tumorcellen om te kunnen vermenigvuldigen. Verlies van een geactiveerde 
MAPK route in metastasecellen zoals in dit proefschrift beschreven, kan daardoor ook voordelen voor de 
tumorcel opleveren en uiteindelijk metastasering bevorderen.
 
Toekomst
De identificatie van de moleculaire pathways die betrokken zijn bij de ontwikkeling van het 
oogmelanoom, kunnen in de toekomst leiden tot effectieve therapieën voor het gemetastaseerde 
oogmelanoom. De identificatie van mutaties, zoals GNAQ en GNA11, die invloed hebben op de groei van 
de tumor en het ontrafelen van de moleculaire basis van het verband tussen het verlies van chromosoom 
3 en metastasering, kan helpen bij de zoektocht naar nieuwe geneesmiddelen. Zoals weergegeven 
in dit proefschrift, zijn tumoren vaak heterogeen en zullen niet alle cellen van de tumor op dezelfde 
manier reageren. Zo kunnen cellen in metastasen een subkloon zijn van de primaire tumor en daarom 
verschillende karakteristieken hebben. Onderzoek met behulp van materiaal van de primaire tumor 
van patiënt en diens metastasen zal essentieel zijn om nieuwe therapieën te ontwikkelen, hetgeen kan 
leiden tot individueel gerichte therapie om lange-termijn overleving mogelijk te verbeteren.
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